Innate immunity: current understandings and future perspectives Authors: Chaoyu Zou, Teng Ma, Jing Li, Xikun Zhou Published: 2026 ABSTRACT AbstractInnate immunity constitutes the body’s first line of defense, deploying evolutionarily conserved mechanisms to detect and respond to pathogenic threats and tissue injury. In contrast to the adaptive immune system’s specificity and memory, innate immunity relies on germline-encoded pattern recognition receptors (PRRs) to sense pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). This review outlines the major PRR families and their downstream signaling pathways, culminating in the production of cytokines and inflammasome activation. Additionally, this review explores the functional integration of cellular responses and examines the sophisticated regulatory circuits, including transcriptional, posttranscriptional, epigenetic, and metabolic mechanisms, that calibrate innate immune responses. Importantly, we highlight how dysregulated innate immunity underlies a wide spectrum of diseases, from autoinflammatory and autoimmune disorders to chronic inflammatory states and cancer. Recent insights into trained immunity and innate immune memory further redefine the scope of innate defenses, revealing that metabolic and epigenetic remodeling can prime innate cells for enhanced secondary responses. Finally, we discuss the therapeutic potential of modulating innate pathways, including PRR agonists as vaccine adjuvants or anticancer agents, and PRR inhibitors in autoimmune and inflammatory diseases. By integrating current mechanistic knowledge with emerging therapeutic strategies, this review underscores the central role of innate immunity in health and disease while pointing toward promising avenues for future research and clinical translation.Subject terms: Innate immunity, Immunological disorders Introduction Innate immunity represents an evolutionarily ancient, nonspecific defensive system that constitutes the first line of host protection against pathogens and tissue perturbation, acting through hard-wired cellular and molecular circuits that preconfigure host protection before antigen-specific responses emerge.1–3 Comprising myeloid phagocytes (neutrophils, monocytes/macrophages, dendritic cells (DCs)), granulocytes (eosinophils, basophils, mast cells), innate lymphocytes (NK cells and ILCs), and epithelial/barrier cells, the innate system senses perturbations via pattern recognition receptors (PRRs) and translates them into antimicrobial, antiviral, and tissue-repair programs.4–6 Unlike adaptive lymphocytes, which expand clones bearing somatically rearranged TCR/BCR specificities, innate cells deploy germline-encoded sensors and effector modules to deliver immediate protection and to shape subsequent adaptive responses.2,7 The conceptual framework of innate immunity advanced sharply in the late 20th century. In the late 1980s, Charles Janeway proposed the “PAMP-PRR” hypothesis, positing that germline-encoded receptors recognize conserved microbial signatures and thereby initiate adaptive responses.8 This represented a paradigm shift in which innate signals were linked to adaptive activation through costimulatory pathways. Subsequently, Matzinger’s “danger model” further emphasized the role of endogenous damage signals as triggers of sterile inflammation.9 In the 1990s, key PRRs were discovered. Notably, the Drosophila Toll gene was shown to mediate antifungal defense, and homologous mammalian Toll-like receptors (TLRs) were identified.10–12 Since then, multiple PRR families have been defined. Currently, five major groups (TLRs, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs), and absent in melanoma-2 (AIM2)-like receptors (ALRs)) are recognized, and each is tailored to particular pathogen patterns. The discovery of additional sensors, including cytosolic nucleic acid sensors and inflammasome components, has continually refined the current understanding of innate recognition. Collectively, these advances cemented innate immunity as a field with precise molecular logic and therapeutic reach (Fig. 1). Key discoveries in innate immunity. The historical trajectory of seminal discoveries in innate immunity is delineated. The journey began in the 1880s with the identification of phagocytes capable of actively engulfing foreign particles, establishing the cellular foundation of innate immunity. This was followed by the discovery of the DCs and NKs, the elucidation of the complement system, the proposal and subsequent validation of the PRR paradigm, and the discovery of pivotal signaling pathways. The narrative extends to recent conceptual advancements, including the proposal of trained immunity and the emerging concept of ancestral immunity. This figure was created with BioRender (http://biorender.com/) Functionally, innate immunity pivots on several core modules. PRR-based detection via TLRs, RLRs, NLRs, and cytosolic DNA sensors initiates transcriptional and posttranscriptional programs that include inflammatory cytokines, chemokines, type I/III interferons (IFNs), and inflammasome activation. These mediators recruit and activate other immune cells and establish an inflammatory environment. Cellular clearance mechanisms, such as phagocytosis, neutrophil extracellular traps (NETs), and cytotoxic granule release, eliminate pathogens and damaged cells while broadcasting danger and repair cues to the tissue milieu. Moreover, complement integrates with coagulation and cell-intrinsic defenses to opsonize targets, form lytic pores, and tune inflammation. Additionally, local and systemic inflammatory circuits coordinate cytokines, alarmin release, and pyroptotic cell death, balancing microbial control with host tissue integrity.13 Such innate responses are generally protective. However, their dual nature means that excessive or chronic activation can result in host damage. Indeed, dysregulated cytokine release or inflammasome activity underlies septic shock and autoinflammatory diseases, and chronic innate inflammation contributes to autoimmunity and cancer.14,15 Thus, innate immunity must be tightly regulated to balance protection against pathology. This review presents an updated overview of the core signaling pathways and sophisticated regulatory networks governing innate immune responses. We elaborate the molecular mechanisms by which PRR activation initiates downstream signaling cascades and further dissect the multifaceted modulation of these signaling networks via negative feedback inhibitors, cell type-specific determinants, and epigenetic programming. Moreover, this review discusses recent translational advances in innate immune manipulation, ranging from the application of TLR agonists as vaccine adjuvants and cancer immunotherapeutic agents to the utilization of PRR antagonists for the treatment of chronic inflammatory and autoimmune disorders. Finally, we outline the unresolved key challenges in the field and propose promising directions for future in-depth investigation. Core components and signaling pathways of innate immunity The current understanding of innate immune signaling is evolving beyond the conceptualization of a linear collection of receptors and downstream pathways. Emerging evidence supports a modular and system-level architecture in which distinct PRRs function as core components of spatially segregated yet functionally interconnected sensing modules. These modules cooperatively govern three fundamental processes, including danger sensing, signal amplification and systemic dissemination. This modular organization enables the host to rapidly mobilize either pro-inflammatory or anti-inflammatory responses as needed to adapt to diverse environmental conditions. Spatial compartmentalization of PRR sensing Innate immunity relies upon a distributed surveillance apparatus that perpetually monitors the extracellular space, endosomal compartments, and cytosol for molecular signatures indicative of infection or tissue injury. PRRs do not operate as isolated receptor families but rather function as integral components of spatially segregated sensing modules. This organizational principle involves more than anatomical distribution. The operational niche of a receptor shapes its ligand specificity, signaling mechanisms, and cellular safeguards against self-recognition. Major PRR families include TLRs, NLRs, RLRs, CLRs, and ALRs (Table 1).16 These receptors localize to membranes, endosomes, or the cytosol to survey and recognize pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) in the extracellular and intracellular environments.17 In this section, the major PRR families are organized and discussed according to their subcellular localization and functional domains. A detailed discussion of soluble and other receptors within this broader context can be found in specialized reviews on pattern recognition molecules (PRMs). Table 1Overview of major PRRsFamilyPRRsLocalizationLigandCore adaptorCanonical functionTLRTLR1/TLR2 heterodimerPlasma membraneTriacyl lipopeptidesMyD88Inflammatory responses and IFN responsesTLR6/TLR2 heterodimerPlasma membraneDiacyl lipopeptidesMyD88TLR4Plasma membrane/EndosomesLPS, viral proteins, DAMPsSurface:MyD88; Endosomes:TRIFTLR5Plasma membraneFlagellinMyD88TLR3EndosomesdsRNA, Poly(I:C)TRIFTLR7, TLR8EndosomesssRNAMyD88TLR9EndosomesUnmethylated CpG DNA, malaria-derived hemozoinMyD88TLR11, TLR12 (mouse)EndosomesProfilin-like protein (T. gondii)MyD88TLR13 (mouse)EndosomesBacterial 23S rRNAMyD88TLR10 (human)Plasma membrane/EndosomesDefinitive ligands remain unresolvedIncompletely definedIncompletely definedNLRNLRB: NAIPCytosolBacterial flagellin, T3SS rod/needle proteinsNLRC4Initiates NAIP-NLRC4 inflammasome activation, leading to caspase-1 activation, IL-1β/IL-18 maturation and pyroptosisNLRC: NOD1,NOD2CytosolNOD1:iE-DAP; NOD2:MDPRIPK2Activates NF-κB and MAPK signaling to induce inflammatory cytokines, chemokines and antimicrobial responsesRLRRIG-ICytosolShort dsRNA with 5′-triphosphate/blunt endsMAVSType I/III IFN and proinflammatory cytokines inductionMDA5CytosolLong dsRNACLRDectin-1 (CLEC7A)Plasma membraneβ-glucans, vimentin, galectinsSyk/CARD9FcRγFcRγDrives antifungal cytokine production, phagocytosis, ROS production and trained immunity-related signalingDectin-2 (CLEC6A)Plasma membraneα-mannans/high-mannosePromotes antifungal inflammatory responses and Th17-polarizing cytokine productionMinclePlasma membraneTDM/SAP130Induces inflammatory cytokines and myeloid activation during fungal, mycobacterial and sterile inflammatory responsesALRAIM2CytosoldsDNAASCIL-1β/IL-18 production, regulation of pyroptosis and IFN programsIFI16Cytosol/nucleusdsDNADAMPs danger-associated molecular patterns, iE-DAP γ-D-Glu-meso-diaminopimelic acid, MDP muramyl dipeptide, RIPK2 receptor-interacting serine/threonine-protein kinase 2, MAVS mitochondrial antiviral-signaling protein, TDM Trehalose-6,6’-dimycolate, SAP130 SIN3A associated protein 130, ASC apoptosis-associated speck-like protein containing a CARD Overview of major PRRs Syk/CARD9 FcRγ FcRγ DAMPs danger-associated molecular patterns, iE-DAP γ-D-Glu-meso-diaminopimelic acid, MDP muramyl dipeptide, RIPK2 receptor-interacting serine/threonine-protein kinase 2, MAVS mitochondrial antiviral-signaling protein, TDM Trehalose-6,6’-dimycolate, SAP130 SIN3A associated protein 130, ASC apoptosis-associated speck-like protein containing a CARD Plasma membrane receptors in front-line surveillance A subset of TLRs and the major identified CLR family localize to the plasma membrane and possess transmembrane domains. However, their ligand repertoires differ substantially, a distinction primarily attributable to variations in the architecture of their structures. The ligands they recognize are highly diverse, including proteins, lipids, glycolipids and carbohydrates. TLRs represent the prototypical family of PRRs and are widely expressed on innate immune cells such as macrophages, DCs, and neutrophils, as well as on a subset of T cells and B cells to regulate immune responses. Across the metazoan lineage, TLR-encoding genes are found in organisms ranging from invertebrates to humans, with different species encoding varying numbers of TLRs. For example, humans possess 10 TLRs (TLR1 to TLR10), while mice have 12 (TLR1 to TLR9 and TLR11 to TLR13; TLR10 is a pseudogene in mice).18–22 All TLRs share a conserved architecture consisting of extracellular leucine-rich repeat (LRR) domains responsible for ligand recognition, a single transmembrane domain, and an intracellular Toll/interleukin-1 receptor domain that mediates downstream signal transduction (Fig. 2a). Regardless of their subtypes, all TLRs exhibit similar structural architectures that perform analogous functions. These observations collectively suggest that TLRs represent an ancient and evolutionarily conserved defense mechanism against the different molecular patterns of microorganisms and self-components. Structure, ligand recognition, and signaling pathways of the Toll-like receptor family. a Representative architecture of TLRs. b Subcellular localization of prototypical TLRs and their cognate PAMPs. c Canonical TLR signaling cascades. The upper panel (red arrows) depicts extracellular PAMPs engaging TLR2/TLR6/TLR1, leading to MyD88 recruitment. MyD88 recruits IRAK1/4, which cooperate with Ubc13 and Uev1A to promote TRAF6 ubiquitination. Polyubiquitinated TRAF6 recruits the TAK1-TAB1/2/3 complex, resulting in TAK1 phosphorylation. Activated TAK1 subsequently stimulates the NEMO-IKKβ-IKKα complex to phosphorylate and degrade IκB, thereby releasing NF-κB for transcriptional activation. In parallel, TAK1 also activates MAPKs, culminating in AP-1-mediated transcription. The lower panel (blue arrows) shows intracellular dsRNA recognition by TLR3, which signals through TRIF to induce TRAF3 ubiquitination. Activated TRAF3 phosphorylates the NEMO-TANK-IKKε-TBK1 complex, leading to IRF3 phosphorylation and transcriptional activation. This figure was created with BioRender (http://biorender.com/) Mammalian TLRs that are strategically located either on the plasma membrane, including TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10, detect microbial cell components, primarily proteins and lipids (Fig. 2b). TLR2 recognizes lipoproteins of bacteria and Mycoplasma by forming a heterodimer with either TLR1 or TLR6. The resulting TLR2-TLR1 or TLR2-TLR6 heterodimers recognize tri- or diacylated lipoproteins, respectively, yet heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum without leading to differential signaling (Fig. 2c). Human TLR10, which shares genetic homology with TLR1 and TLR6, is considered functionally active, yet its definitive ligand remains elusive. TLR4 and TLR5 specifically recognize distinct microbial cell surface components. Lipopolysaccharide (LPS) is recognized by the TLR4-MD-2 complex with the aid of CD14, thereby inducing MyD88-mediated inflammatory responses at the plasma membrane.11,23 Upon LPS stimulation, TLR4 can be translocated to the endosome, where it triggers the TRAM-TRIF pathway to induce type I interferon signaling.24 Beyond this, TLR4 can directly bind to viral envelope proteins and indirectly respond to DAMPs triggered by viral infections.25,26 TLR5 detects a conserved D1 motif in bacterial flagellin and thereby initiates MyD88-dependent inflammatory responses against many motile bacteria.27 This surveillance is counteracted by several flagellated pathogens through sequence variation within the TLR5-interacting region of flagellin. Helicobacter pylori represents a well-characterized example, as its FlaA carries substitutions that markedly reduce flagellin-dependent TLR5 activation while preserving motility.28 However, H. pylori does not simply abolish TLR5 engagement, since cag pathogenicity island-positive strains can activate TLR5 through the type IV secretion system component CagL, suggesting a rewired mode of TLR5 sensing rather than complete immune invisibility.29 CLRs are transmembrane receptors characterized by one or more C-type lectin-like domains (CTLDs) in their extracellular regions, and many possess immunoreceptor tyrosine-based activation motif (ITAM) or half-ITAM (hemITAM) sequences in their cytoplasmic tails.30 CLRs exhibit a broad ligand recognition spectrum via CTLDs, including carbohydrates, proteins, and lipids from pathogens (fungi, bacteria, viruses) as well as endogenous molecules sensed by specific CLRs.30 For example, Dectin-1 (CLEC7A), functioning as the β-glucan receptor that plays a central role in initiating and regulating trained immunity, binds not only fungal β-glucans but also multiple self-derived molecules, particularly vimentin, galectins, and galactosylated immunoglobulins.31 Upon ligand engagement, CLRs transduce signals through either ITAM or ITIM motifs. Activating receptors such as Dectin-1 engage the SYK/CARD9 pathway to induce cytokine secretion, phagocytosis, and Th17 differentiation. In contrast, inhibitory receptors such as DCIR/CLEC4A recruit phosphatases to maintain immune homeostasis.30,32 Endosomal receptors in compartmentalized sensing Only a limited number of PRRs have been identified on the membranes of intracellular membranous organelles, with the main PRRs currently known to belong to several types of TLRs, including TLR3, TLR7, TLR8, TLR9, TLR11, TLR12 and TLR13. They play pivotal roles in detecting nucleic acids derived from microbes, as well as self-RNA or self-DNA in pathogenic contexts, and initiating innate immune responses (Fig. 2b). TLR3 recognizes viral double-stranded RNA (dsRNA), as well as the synthetic dsRNA analog polyinosinic-polycytidylic acid (Poly(I:C)) (Fig. 2c).33 TLR7 and TLR8 activate host responses against viral and bacterial pathogens by detecting pathogen-derived single-stranded RNA (ssRNA).34–36 TLR9, primarily expressed in human plasmacytoid dendritic cells (pDCs) and B cells as well as murine monocytes and macrophages, detects unmethylated cytosine-phosphate-guanine (CpG) DNA from bacteria/viruses and synthetic CpG ODNs while also recognizing the 2′-deoxyribose backbone.15,37 Additionally, TLR9 interacts with malaria-derived hemozoin, either directly or by facilitating parasite DNA delivery to endosomes, although its precise role in malaria immunity remains debated.38,39 TLR11, which is present in mice but not in humans, shares homology with TLR5 and can recognize the profilin-like molecule Toxoplasma gondii, inducing DCs to produce interleukin-12 (IL-12). TLR12 exhibits functions similar to those of TLR11 in mice.40,41 Mouse TLR13 recognizes a highly conserved sequence within bacterial 23S ribosomal RNA.42,43 Cytosolic receptors in intracellular surveillance While plasma membrane and endosomal receptors monitor extracellular and endocytosed threats, many pathogens replicate in the cytosol or deliver products directly into the cytoplasm. Cytosolic PRRs therefore constitute an essential surveillance layer for detecting intracellular infection, microbial invasion, and stress-associated danger signals. This category of PRRs primarily comprises the NLR, RLR, and ALR families. The nucleotide-binding and leucine-rich repeat-containing receptor family was initially discovered in plants and is currently recognized as the largest known family of disease-resistance genes in plants.44 Subsequently, similar domains were identified and characterized in mammals based on sequence homology, designated NLR. NLRs are cytosolic PRRs that detect intracellular microbial components, metabolic disturbances, and cellular stress. They typically consist of a central nucleotide-binding and oligomerization (NACHT) domain, a C-terminal LRR for ligand sensing, and an N-terminal effector domain that functions to activate diverse intracellular downstream signaling pathways. Based on the distinct N-terminal domains, mammalian NLRs are classified into five subfamilies: NLRA (acidic transactivation domain), NLRB (baculovirus inhibitor of apoptosis protein repeat, BIR), NLRC (caspase activation and recruitment domain, CARD), NLRP (pyrin domain (PYD)), and NLRX, which contains other distinct N-terminal effector domains. The following sections provide a general overview of the functions of these five NLR subtypes. Major histocompatibility complex (MHC) class II transactivator (CIITA), the unique NLRA member, is a non-DNA-binding coactivator that is recruited to MHC class II promoters through interactions with the MHC class II enhanceosome, thereby coordinating MHC class II gene transcription.45 It is constitutively expressed in antigen-presenting cells and is inducible by interferon gamma in monocytes. 46,47 Therefore, it acts as a bridge between innate and adaptive immunity. Current research on CIITA-related diseases, including human immunodeficiency virus (HIV)/microbial infections and cancer, largely focuses on its role in regulating MHC class II expression. Additional functions of CIITA, as well as the identification of other members within the NLR family, require further extensive research. NLRB, also known as the NLR family apoptosis inhibitory protein (NAIP) subfamily, recognizes microbial components, including bacterial flagellin and type III secretion system rod and needle proteins.48,49 Upon PAMP recognition, these NAIPs recruit NLRC4 and facilitate the formation of the NLRC4 inflammasome, which activates caspase-1 and induces pyroptosis in intestinal epithelial and myeloid cells.50 NOD1 and NOD2 sense bacterial peptidoglycan fragments and, upon activation, recruit RIPK2 through their N-terminal CARDs, thereby triggering NF-κB and mitogen-activated protein kinase (MAPK) signaling.51 Within the NLRC subfamily, NLRC5 functions analogously to CIITA as a master transactivator of MHC class I genes in lymphoid and myeloid cells, and its loss or epigenetic silencing contributes to tumor immune evasion and poor prognosis in cancers.52 Beyond this canonical role, NLRC5 has also been implicated in antiviral and inflammatory signaling, although the reported findings are not fully consistent. One line of evidence suggests that NLRC5 supports antiviral responses, as it is induced by Sendai virus or poly(I:C), and NLRC5 knockdown reduces type I interferon-related responses in human cells.53 Conversely, another study reported inhibitory effects of NLRC5 on the NF-κB and type I interferon pathways through interactions with IKK-α/β, RIG-I and MDA5.54 These observations suggest that, unlike its clearly defined role in MHC class I transcription, the functions of NLRC5 in innate immune signaling are likely context dependent and remain incompletely resolved. Furthermore, recent studies have demonstrated that NLRC5 can mediate PANoptosis under heme and LPS stimulation by interacting with NLRP12 and PANoptosome components, thereby promoting the assembly of a cell death complex.55 The NLRP subfamily, defined by an N-terminal PYD, encompasses canonical inflammasome sensors. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome is the most well-studied in the NLR family and is activated by diverse signals, such as potassium efflux, mitochondrial dysfunction, and reactive oxygen species (ROS).56,57 NLRX1, currently the only member of the NLRX subfamily, utilizes its N-terminal mitochondrial targeting sequence to localize dynamically within mitochondria. It functions as a context-dependent regulator. While proposed to inhibit stimulator of interferon genes (STING)-dependent antiviral signaling involving IFN-I and NF-κB, it also promotes context-dependent antiviral responses via ROS, JNK, and IRF1 regulation. Moreover, it critically governs autophagy/mitophagy pathways through interactions such as those with TUFM-ATG5-ATG12 and LC3, representing a potential therapeutic vulnerability.58–62 RLRs are intracellular PRRs, including RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2), that sense viral RNAs to initiate innate antiviral responses. RIG-I and MDA5 possess tandem N-terminal CARDs for downstream signaling, a central helicase domain, and a C-terminal domain that is responsible for the recognition of viral RNA.63 LGP2 lacks tandem CARDs and is widely recognized as a regulatory modulator that influences viral RNA recognition by RIG-I and MDA5.64 Viral RNA binding triggers an ATP-dependent conformational change and filament formation, exposing CARDs to recruit mitochondrial antiviral-signaling protein (MAVS) on mitochondria. MAVS then activates TANK-binding kinase 1 (TBK1)/inhibitor of kappa B kinase (IKK) ε to phosphorylate interferon regulatory factor 3/7 (IRF3/7) and NF-κB pathways, leading to type I IFN and pro-inflammatory gene expression.63 ALRs include AIM2 and IFI16 (interferon gamma-inducible protein 16), which recognize dsDNA in the cytoplasm or nucleus, respectively. AIM2, the most extensively studied member of this family, detects double-stranded DNA via a C-terminal HIN-200 domain and oligomerizes via an N-terminal PYD to initiate inflammasome assembly. Upon dsDNA binding, AIM2 molecules filament along DNA in a length-dependent manner to nucleate apoptosis-associated speck-like protein containing a CARD (ASC) via PYD-PYD interactions, forming helical filaments that recruit caspase-1 through CARD interactions. Activated caspase-1 cleaves pro-IL-1β and pro-IL-18 into their bioactive forms and drives pyroptosis.57 In addition, several innate immune receptors do not conform to the structural characteristics of classical PRR families. Notably, cytosolic alpha-kinase 1 (ALPK1) has been recently shown to detect bacterial ADP-heptose, while DLM-1/ZBP1 senses cytosolic DNA, thereby activating innate immune signaling.65,66 Extracellular soluble PRMs, such as pentraxins, collectins, and ficolins, constitute an additional class of pathogen-sensing receptors. However, they are not discussed here due to space limitations. Overall, these sensors broaden innate immune surveillance and allow the host to respond to diverse infections and stress signals. Targeting these pathways holds promise for both boosting host defense and treating inflammatory diseases. In summary, organizing PRRs into plasma membrane, endosomal, and cytosolic categories underscores the spatial organization of innate immune recognition. Plasma membrane PRRs mediate rapid surveillance of extracellular cues, endosomal PRRs support compartment-restricted sensing of nucleic acids, and cytosolic PRRs detect intracellular infection and cellular stress, eliciting robust antiviral responses and inflammasome activation. Together, this spatial arrangement broadens pathogen detection while minimizing inappropriate responses to self-derived ligands, enabling effective host defense with limited immunopathology. Signal amplification modules Innate immune sensors often encounter microbial products or danger cues in limited amounts, yet they must trigger rapid and durable transcriptional and inflammatory programs. This is accomplished largely through adaptors that assemble at the receptor and concentrate shared signaling factors, thereby converting short-lived receptor engagement into sustained activation of kinase modules and transcription factors (TFs). In parallel, inflammasomes provide an amplification route that links upstream sensing to inflammatory caspase activation and the maturation of IL-1 family cytokines, producing a rapid and potent inflammatory output. Many innate pathways therefore rely on cooperative assembly of multiprotein complexes that impose activation thresholds and support signal persistence while still allowing multiple points of negative regulation to restrain excessive inflammation. Adaptor-mediated signal amplification Adaptors serve as central sites of innate immune signal amplification because they convert limited receptor engagement into the assembly of signaling complexes that recruit shared kinase hubs and TFs. A useful way to rationalize this process is to align adaptor usage with PRR spatial positioning. Plasma membrane, endosomal and cytosolic PRRs operate under different constraints on ligand access and compartmentalization, and these constraints shape which adaptors are engaged, how quickly they assemble and which outputs dominate. Plasma membrane PRRs are optimized for the fast detection of extracellular microbes and therefore depend on adaptors that assemble rapidly and sustain inflammatory transcriptional programs. For many surface TLRs, signaling converges on myeloid differentiation primary response 88 (MyD88), which oligomerizes with IRAK kinases to form the myddosome. Structural work established that the MyD88-IRAK4-IRAK2 death domain complex forms a helical oligomer that promotes proximity-dependent IRAK activation, providing a mechanistic basis for how low-level receptor engagement is amplified into NF-κB and MAPK activation.67 A recent high-impact synthesis of TLR biology reinforces that adaptor choice is a major determinant of output, with MyD88-dominant pathways preferentially driving early inflammatory cytokines and chemokines that coordinate leukocyte recruitment and activation.17 A related logic applies to membrane CLRs in myeloid cells. Although proximal signaling commonly involves SYK, signal gain and program selection often depend on the CARD9 axis, which integrates inputs from multiple ITAM- or hemITAM-bearing receptors to shape downstream inflammatory gene expression. Recent human genetics and mechanistic work support this hub model by identifying a CARD9 phosphorylation switch required for full inflammatory competence and demonstrating that disease-associated variation can rewire antifungal immunity in vivo.68 Endosomal PRRs, especially nucleic acid-sensing TLRs, must combine high sensitivity with safeguards against self-nucleic acids. In this compartment, amplification is coupled to adaptor usage that favors IFN-competent signaling. Under appropriate trafficking conditions, TLR3 and endosomal TLR4 signal through TIR domain-containing adapter-inducing interferon-beta (TRIF), which recruits TBK1-associated machinery and supports IRF3 activation while retaining access to NF-κB modules. A structural framework for this step has been provided by defining how phosphorylated adaptor elements engage IRF3 in a coordinated manner, helping to explain why efficient IFN induction depends on ordered assembly events rather than simple TBK1 recruitment alone.69 These principles align with updated views that endosomal localization and adaptor selection together set the balance between inflammatory and antiviral outputs.17 Cytosolic PRRs often amplify signaling through membrane-anchored adaptor assemblies that behave as cooperative switches. In the RLR pathway, RIG-I and MDA5 converge on MAVS in mitochondria, where higher-order MAVS assemblies nucleate the TBK1 and IKK modules to drive coordinated IRF and NF-κB activation. Recent work shows that cellular RNA can directly support MAVS signalosome function, highlighting an additional layer of platform organization beyond receptor binding.70 A complementary checkpoint is provided by MAVS palmitoylation, which promotes MAVS aggregation and timely type I IFN responses in vivo.71 For cytosolic DNA sensing, cGAS-generated signals converge on STING, whose activation involves trafficking and clustering at the trans-Golgi network. Single-molecule imaging provides direct evidence that STING clustering enhances TBK1 association and thereby increases signaling efficiency.72 For bacterial peptidoglycan sensing, NOD1 and NOD2 signal through RIPK2, which couples receptor oligomerization to ubiquitin-dependent scaffolding that sustains NF-κB and MAPK activation. Recent medicinal chemistry perspectives emphasize RIPK2 as a central amplification node and a tractable therapeutic target in inflammatory disease contexts.73 Taken together, this spatially organized adaptor framework supports three linked claims. First, amplification is primarily an adaptor property because adaptors determine whether cooperative assembly occurs and which kinase hubs are engaged. Second, spatial positioning constrains adaptor selection and thereby shapes signaling outputs. Surface receptors tend to favor rapid inflammatory responses, endosomal receptors are more closely linked to IFN-biased signaling, and cytosolic receptors often rely on membrane-anchored clustering for switch-like activation. Third, recent mechanistic evidence increasingly points to posttranslational checkpoints such as palmitoylation and trafficking-dependent clustering as tunable regulators of adaptor competence and signal gain. Inflammasomes as amplification and effector hubs Inflammasomes are cytosolic supramolecular signaling assemblies that translate the detection of infection or cellular damage into rapid inflammatory outputs. Their defining feature is assembly-driven amplification. Ligand sensing promotes the formation of large multiprotein platforms that concentrate inflammatory caspases and their substrates, thereby enabling decisive activation even when the initiating stimulus is scarce. This organization supports two tightly coupled effector arms, maturation of IL-1 family cytokines such as IL-1β and IL-18, and pyroptotic cell death through gasdermin pore formation. At the same time, the requirement for cooperative assembly imposes activation thresholds and provides multiple points for negative regulation, which helps limit collateral tissue injury. These general principles provide a coherent foundation for discussing canonical and noncanonical inflammasome pathways in parallel with their shared structural logic. In terms of classification, it is practical to organize inflammasome signaling by pathway logic into canonical and noncanonical routes while keeping the structural vocabulary consistent across both. Canonical inflammasomes are typically initiated by sensor activation that recruits the adaptors ASC and pro-caspase-1, leading to caspase-1 activation, maturation of interleukin-1 (IL-1) family cytokines, and execution of pyroptosis. Recent structural work strengthens the view that canonical activation is governed by cooperative oligomerization, not simply by the presence or absence of a ligand. Cryo-EM analysis revealed disc-shaped active NLRP3 assemblies and clarified how the recruitment of ASC and caspase-1 can be organized within higher-order oligomers.74 Complementing this, a 2024 structural and computational study provided a mechanistic model for oligomerization-facilitated activation, explicitly arguing that cooperative transitions in NLRP3 oligomer states can encode signal thresholds.75 Functionally, canonical signaling also depends on priming processes that shape the availability and positioning of components. A primary study connected classical NF-κB priming to inflammasome assembly by showing that IKKβ promotes recruitment of NLRP3 to PI4P-enriched trans-Golgi membranes and can thereby enable inflammasome formation under specific conditions.76 Together, these studies support a coherent framework in which canonical inflammasomes act as structurally defined amplifiers that integrate cellular stress signals, compartmental cues, and cooperative assembly to generate interleukin-1 beta (IL-1β)- and interleukin-18 (IL-18)-driven inflammation while limiting inappropriate activation through built-in thresholds. Noncanonical inflammasome signaling is organized differently because the sensor function is embedded within inflammatory caspases themselves. In this route, human caspase-4, caspase-5 and murine caspase-11 directly respond to cytosolic LPS, triggering effector activation that culminates in gasdermin D cleavage and pyroptosis. A foundational demonstration of this execution logic showed that caspase-11 cleavage of gasdermin D is central to noncanonical signaling outputs.77 Recent primary studies have refined how noncanonical signaling is initiated and constrained in human cells. Santos and colleagues showed that human GBP1 can bind LPS on cytosolic bacteria and assemble a platform that promotes caspase-4 recruitment and activation, providing a mechanistic bridge between IFN-induced cell-autonomous immunity and noncanonical inflammasome triggering.78 A striking advance in pathway output came from the finding that activated human caspase-4 can directly process IL-18, revealing that noncanonical signaling is not limited to pyroptosis and can contribute directly to cytokine maturation in infection settings.79 Importantly, the pathway also contains dedicated brakes. A recent study reported that mitochondrial cardiolipin can inhibit the noncanonical inflammasome by preventing LPS binding to caspase-4 and caspase-11, providing a lipid-based mechanism that restrains runaway cytosolic LPS sensing.80 Taken together, canonical and noncanonical inflammasomes can be described within a single narrative that links structure to function. Canonical signaling emphasizes adaptor-mediated assembly and caspase-1-dependent cytokine maturation, whereas noncanonical signaling emphasizes direct cytosolic LPS recognition by inflammatory caspases with strong pyroptotic output and additional cytokine control. Both routes shape innate immunity by enabling rapid elimination of infected cells, reinforcement of barrier and myeloid responses, and orchestration of downstream adaptive immunity while also carrying clear risk for tissue injury when activation thresholds or inhibitory checkpoints fail. Limited by space, detailed structural and functional distinctions among individual inflammasome families are not expanded here, and readers are referred to established reviews for comprehensive coverage.81,82 System-level dissemination logic in innate immunity Innate immune sensing is usually local, yet its consequences must be coordinated across space and time. The host must translate focal sensing into coordinated changes across the epithelium, endothelium, stroma and circulating leukocytes while still preserving context, such as the nature of the threat and the anatomical site. In this section, dissemination is organized into two tightly coupled communication layers, cytokines and chemokines (Table 2), followed by the complement system as an autonomous humoral coordinator that interfaces with but is not reducible to cytokine and chemokine logic. This organization keeps the molecular content unchanged while making explicit how innate immunity scales from single cells to tissues and, when needed, to the whole organism. Table 2Classification and functions of major inflammatory factorsFamilyRepresentative membersMain innate sourcesReceptors/signaling (typical)Key innate functionsInterleukins (ILs)IL-1 family (IL-1α/β, IL-18, IL-33, IL-37), IL-6 family (IL-6, OSM, LIF), IL-12 family (IL-12/23/27/35), IL-10 family (IL-10, IFN-λs share IL10R2 chain)Macrophages, DCs, epithelial cells, NK, etc.Many via JAK-STAT, gp130 for IL-6 family, IL-12/23 heterodimers with specific receptor pairs → STAT1/3/4; IL-1 family → MyD88-IRAK-NF-κB/MAPKsFever/acute-phase, leukocyte recruitment, phagocyte activation, polarization of lymphocytes, anti-inflammatory brakes (IL-10/IL-37)Colony-stimulating factors (CSFs)GM-CSF (CSF2), M-CSF (CSF1), G-CSF (CSF3), (EPO/SCF/TPO pleiotropic in hematopoiesis)Stroma, endothelium, macrophagesCSF2R/CSF1R/CSF3R → JAK2-STAT5, PI3K-AKT, MAPKMyelopoiesis, macrophage maturation/survival, neutrophil production/mobilization and functionInterferons (IFNs)Type I: IFN-α/β, Type II: IFN-γ, Type III: IFN-λ1-3Macrophages, pDCs, epithelia, NK, etc.IFNAR1/2 (JAK1/TYK2 → STAT1/2), IFNGR1/2 (JAK1/JAK2 → STAT1), IFNLR1/IL10R2 (JAK1/TYK2→STATs)Induce ISGs and antiviral state, augment phagocyte antimicrobial programs, mucosal protection by type III with limited systemic inflammationTNF superfamily (TNFs)TNF-α, TNF-β, other TNFSF membersMonocytes/macrophages, NK, etc.TNFR1/2 → NF-κB, MAPKs, death-pathway cross-talkStrong pro-inflammatory drive, endothelial activation, synergy with IFN-γGrowth factors (GFs)VEGF, FGF, EGF, TGF-β, SCF, etc.Multiple tissue/immune cellsRTKs (VEGFR/FGFR/EGFR) or TGFβR (Ser/Thr kinase) → SMAD and non-SMADAngiogenesis and tissue repair at inflamed sites, context-dependent immune modulationChemokinesCC: CCL2/3/5, CXC:CXCL8 (IL-8) (ELR+/ELR- subsets), CX3C:CX3CL1, XC: XCL1/2Broad (innate and stromal)GPCRs CCR/CXCR/CX3CR1/XCR1Leukocyte chemotaxis/positioning (monocytes, neutrophils, NK), coordinate recruitment and resolutionISG interferon-stimulated gene, SMAD small mother against decapentaplegic Classification and functions of major inflammatory factors ISG interferon-stimulated gene, SMAD small mother against decapentaplegic Cytokine-mediated tissue state programs Cytokines are the primary broadcast signals of innate immunity because they can act across multiple cellular lineages and spatial scales. Their broadcast function is not simply to increase inflammation. It imposes a shared tissue state that shapes vascular behavior, leukocyte competence, and local stromal programming. In practice, innate cytokine broadcasting is implemented as a small set of partially redundant mediators whose combinations encode the dominant response mode. Within this broadcast layer, several cytokine groups recur across infection and sterile injury. Early inflammatory alarms are dominated by tumor necrosis factor (TNF) and IL-1 family cytokines. TNF rapidly primes endothelium and stromal cells to upregulate adhesion molecules and inflammatory gene programs, while IL-1β supports fever, vascular permeability, and myeloid activation.83 The IL-1 family also contains tissue damage-associated mediators such as IL-1α and IL-33 that extend broadcast beyond microbial sensing and allow barrier injury to be translated into inflammatory meaning. At the same time, built-in antagonists and decoy mechanisms in the IL-1 system help restrain the uncontrolled spread of this broadcast. A second cytokine class broadcasts systemic reprogramming and resource allocation. IL-6 is central in linking local inflammation to acute phase responses and broader changes in leukocyte survival and differentiation. Colony-stimulating factors provide a more explicit resource allocation signal. G-CSF mobilizes neutrophil production and release, while GM-CSF and M-CSF shape monocyte and macrophage survival, differentiation, and effector readiness. This class of cytokines links peripheral danger sensing to bone marrow output and systemic leukocyte supply. A third broadcast class defines the antiviral state. Type I IFNs enforce an IFN-stimulated gene program across infected and neighboring cells, while type III IFNs implement a related antiviral state that is often most prominent at barrier tissues where receptor distribution can limit systemic exposure. IFN gamma plays a bridging role in early innate settings through NK cell production and strong macrophage licensing, linking cytokine broadcast to intracellular killing capacity. A fourth class links broadcast to tissue remodeling and repair. Growth factors such as VEGF influence endothelial permeability and vascular remodeling, while barrier-associated growth factor circuits, including EGFR-related programs, support epithelial restitution that must be coordinated with antimicrobial states. Transforming growth factor beta (TGF-β) functions as a state-limiting broadcast that can curtail inflammation and shape repair trajectories, although sustained TGF-β signaling can also promote fibrotic outcomes depending on context. Collectively, these growth factor signals ensure that dissemination is coupled to preservation or restoration of tissue integrity, not only to pathogen clearance. Across these cytokine families, two points matter for a mechanistic review. First, cytokine broadcasts are strongly time-structured. Early peaks often synchronize vascular activation and leukocyte recruitment, whereas later low-level persistence can bias resolution, tolerance or immune paralysis. Second, cytokine meaning is combinatorial. The same cytokine can be protective or pathological depending on the accompanying set and the tissue receiving the message, which is consistent with the observation that multicytokine codes can predict complex organism-wide programs better than the abundance of a single mediator. Chemokine routing of leukocyte recruitment and positioning Chemokines are a specialized cytokine subfamily defined by shared cysteine motifs (CCs, CXCs, CX3Cs, and XCs) that signal through seven-transmembrane G-protein-coupled receptors (GPCRs) to direct leukocyte positioning during innate responses and homeostasis. Their family architecture underlies receptor selectivity and cell-type targeting. Chemokines typically act in concert with inflammatory cytokines (such as TNF-α, IL-1β, and IFN-γ) to rapidly induce adhesion molecules and chemokine expression in stromal/endothelial cells, thereby establishing directional cues for incoming innate leukocytes. CC chemokines, such as C-C motif chemokine ligand 2 (CCL2) and CCL3, primarily recruit monocytes and macrophages through CCR2/CCR5, facilitating microbial clearance and antigen presentation.84 This recognition mechanism appears to depend more on strict receptor-ligand pairing rather than being limited to specific cell types. Previous work has shown that CCL2 chemoattracts and recruits a subset of neutrophils characterized by high CCR2 expression, namely, MHC-IIhi neutrophils.85 Among CXC chemokines, CXCL8 (IL-8) robustly attracts neutrophils, which are vital for early antibacterial defenses through pathogen phagocytosis and antimicrobial mediator secretion.84 Chemokine gradients are physically organized by glycosaminoglycan binding on endothelial and matrix surfaces, which immobilizes ligands, stabilizes oligomers, and shapes haptotactic fields that neutrophils and monocytes can read with high spatial fidelity.86 Atypical chemokine receptors further sculpt these fields without canonical G-protein signaling. Instead, they exert regulation through functions such as chemokine scavenging and presentation. For example, ACKR2 helps terminate responses by scavenging inflammatory CC chemokines, while ACKR1 on postcapillary venules guides diapedesis by transcytosing and luminally presenting chemokines.87,88 Together, this multilayered chemokine system enables the innate immune system to eliminate invaders efficiently while minimizing collateral tissue damage. Complement as a humoral coordination network The complement system is a complex network of over 30 soluble and membrane-associated proteins that acts as a first-line effector of innate immunity. Components are primarily synthesized in the liver, with additional local production by tissue-resident cells such as macrophages, endothelial cells, and fibroblasts, allowing both systemic and peripheral complement activity.89 These components circulate as inactive precursors (such as C3, C4 and C5) in plasma or on cell surfaces and are activated by proteolytic cascades, yielding pro-inflammatory anaphylatoxins (C3a and C5a) that recruit and activate immune cells (neutrophils and macrophages) through GPCRs (C3aR and C5aR1/2), opsonins (C3b and iC3b) that directly tag pathogens for phagocytosis via CR1/CR3 receptors, and the membrane attack complex (MAC, C5b-C9) that can induce target cell lysis.90 The complement system is currently known to be activated through three major pathways: the classical pathway, the mannose-binding lectin pathway, and the alternative pathway (Table 3). Although these pathways differ in their initiation mechanisms, they converge on a common terminal sequence involving the activation of complement component C3 and culminating in the formation of the MAC. Nevertheless, the cascade reaction generates numerous distinct biologically active intermediate products throughout the activation process. The generated bioactive fragments, namely C3a and C5a, engage GPCRs (C3aR, C5aR1) on neutrophils, macrophages, endothelial cells, and lymphocytes. This engagement orchestrates chemotaxis, cytokine production, and increased vascular permeability, thereby effectively linking complement activation to cellular inflammation.91 Tight regulation is essential to prevent host damage. Soluble regulators such as factor H and C4-binding protein accelerate the decay of convertases and serve as cofactors for factor I-mediated inactivation of C3b and C4b. In contrast, membrane proteins, including decay-accelerating factor, membrane cofactor protein, and CD59 protect self-surfaces by disrupting convertases or blocking MAC assembly.92,93 Table 3Core mechanisms of the complement activation pathwaysPathwayRecognition and initiationInitiating proteasesC3 convertaseC5 convertasePrincipal effectorsKey regulatory nodesClassical pathwayC1q engagement on surfaces, classically via Fc of antigen-bound antibodiesC1 complex with C1r and C1s drives C4 and C2 cleavageC4b2aC4b2aC3bC3a and C5a as anaphylatoxins; C3b as opsonin; C5b-9 as MACC1 inhibitor restrains initiation; C4BP supports factor I-mediated inactivation of C4b and accelerates decay of C4b-based convertases; membrane regulators including DAF/CD55 and MCP/CD46 limit convertase stability; CD59 restricts MAC assemblyLectin pathwaySoluble pattern-recognition molecules bind microbial carbohydrate signaturesMASP-2, supported by MASP-1, mediates C4 and C2 cleavageC4b2aC4b2aC3bC3a and C5a as anaphylatoxins; C3b as opsonin; C5b-9 as MACC1 inhibitor can restrain lectin initiation; C4BP acts as a cofactor for factor I in C4 control and shows decay-accelerating activity on the C3 convertase; membrane regulators including DAF/CD55, MCP/CD46, and CD59 protect host surfacesAlternative pathwaySpontaneous C3 thioester hydrolysis initiates convertase formation, whereas surface-bound C3b sustains convertase assembly and pathway amplificationFactor B and factor D generate Bb-containing convertases; properdin stabilizes surface convertase activityC3bBb (often stabilized as C3bBbP)C3bBbC3bC3a and C5a as anaphylatoxins; dense C3b deposition as opsonin; C5b-9 as MACFactor H is the major negative regulator in the alternative pathway, limiting convertase formation in fluid phase and on host surfaces; factor I degrades C3b in cofactor-dependent manner; membrane regulators including DAF/CD55 and MCP/CD46 restrict convertases; CD59 blocks MAC assemblyMAC membrane attack complex, MASP mannan-binding lectin-associated serine protease, C4BP C4b-binding protein, DAF decay-accelerating factor, MCP membrane cofactor protein Core mechanisms of the complement activation pathways MAC membrane attack complex, MASP mannan-binding lectin-associated serine protease, C4BP C4b-binding protein, DAF decay-accelerating factor, MCP membrane cofactor protein Upon microbial invasion, the alternative and lectin pathways are activated first. Rapid C3b deposition on bacterial, fungal, or viral surfaces markedly enhances phagocytosis via complement receptors CR1 (CD35) and CR3 (CD11b/CD18) on neutrophils and macrophages, a process termed opsonophagocytosis that clears pathogens with high efficiency.89 Simultaneously, anaphylatoxins C3a and C5a recruit and activate innate effectors, triggering a cascade in which neutrophils undergo oxidative burst and degranulation, monocytes release proinflammatory cytokines, and endothelial cells increase permeability to facilitate leukocyte extravasation.94 C1q recognition of antigen-antibody complexes (immune complexes, ICs) initiates the classical pathway. However, studies have revealed that microorganisms can activate this pathway through binding to C-reactive protein (CRP). Notably, the MAC generated via all three pathways directly lyses susceptible microorganisms, particularly gram-negative bacteria, by disrupting their outer membrane integrity. Beyond its well-established roles in the extracellular space, complement also operates within cells, a concept termed the complosome. Emerging evidence reveals that intracellular complement components, such as C3, C5, and their receptors, are expressed in various immune and nonimmune cells and exert cell-autonomous functions distinct from circulating complement.95,96 As comprehensively reviewed by Erin and colleagues, the complosome participates in a broad spectrum of cellular processes.95 Here we focus on its roles in innate immunity, which can be roughly divided into two categories: sensing exogenous and endogenous danger. Neutrophils serve as a critical rapidly responding innate immune cell type in host defense against pathogenic microbial infections. Studies have shown that complement components C3 and C5 are maintained at high levels in blood-derived neutrophils and monocytes from both humans and mice.97,98 A recent study demonstrated that an M28 family peptidase from Peribacillus frigoritolerans confers protection against MRSA pneumonia by initiating trained immunity through the complosome-phosphatidylcholine axis in macrophages. Mechanistically, complosome-derived C3, via the CFB-C3a-C3aR axis, activates HIF-1α signaling and promotes phosphatidylcholine accumulation, which is essential for establishing this trained immunity phenotype.99 For endogenous sensing, the complosome responds to a broad range of damage-associated signals arising from cellular stress or sterile injury, thereby contributing to the maintenance of cellular homeostasis and the regulation of inflammatory responses.95 Collectively, these findings establish the complosome as a spatially compartmentalized signaling network that integrates the sensing of both exogenous microbial threats and endogenous stress signals within innate immune cells. Regulatory mechanisms of innate immunity Regulation of innate immunity is achieved primarily through controlling the key molecular components and signaling pathways outlined above. Given the diversity of regulatory factors and mechanisms, this chapter focuses on mechanistic layers of control, including the activation and regulation of TFs, epigenetic mechanisms, mRNA splicing and stability, and the contribution of metabolic reprogramming to the modulation of innate immune responses. Regulation of TFs The host rapidly activates innate immunity upon detection of pathogenic microorganisms or DAMPs. Innate immune responses critically rely on several transcription factor families, including NF-κB, IRF, AP-1, STAT, HIF, and NRF2, to induce the expression of downstream immune-associated genes. The activation of TFs requires a cascade of signaling events and precisely orchestrated regulatory mechanisms. Under resting conditions, NF-κB dimers (p65/p50) are sequestered in the cytosol by inhibitory IκB proteins. Upon TLR or cytokine receptor engagement, IκB kinases (IKKs) phosphorylate IκBα, triggering its ubiquitin-mediated degradation and NF-κB nuclear translocation to activate genes such as TNF and interleukin-6 (IL-6).100 Different signaling pathways are highly interconnected, forming intricate molecular networks that mediate synergistic or antagonistic effects through precise regulatory mechanisms. Dysregulation of these networks underlies chronic inflammation, autoimmunity, and cancer. Thus, TFs act as both conductors and gatekeepers of innate immunity, balancing protective responses with tissue homeostasis. The subsequent discussion will examine the molecular pathways responsible for the activation and regulation of core innate immune transcriptional regulators. Positive regulation of TFs Activation of TFs involves multilayered mechanisms that decode immune signals into transcriptional outputs. In most cases, ligand engagement of PRRs triggers signaling cascades that converge on TFs, leading to their nuclear translocation and DNA binding (Fig. 2c). Innate immune-related TFs, including but not limited to NF-κB (p65/p50), IRFs, STATs, AP-1 (c-Fos/c-Jun), C/EBPβ, NRF2, HIF-1α, and ATF3, exhibit diverse activating ligands and mechanisms but largely adhere to the general principles described above. The following section outlines representative activation pathways for several key classes of these factors, highlighting the diversity and commonalities in their regulatory logic. Upon LPS recognition by TLR4 at the plasma membrane, adaptor proteins MyD88 and TRIF recruit IRAK kinases (IRAK1/4) and the E3 ubiquitin ligase TRAF6. TRAF6 mediates K63-linked ubiquitin chain assembly on itself and on NEMO (IKKγ), forming a platform for the TAK1-TAB2/3 complex. Activated TAK1 phosphorylates the IKKα/β catalytic subunits, which in turn phosphorylate IκBα at Ser32/36, marking it for K48-linked ubiquitination and proteasomal degradation. Freed NF-κB dimers translocate to κB elements in promoters and enhancers of inflammatory genes, including TNF, IL-1β, and IL-6, initiating robust transcription within minutes.101 An identical upstream signal can activate distinct TFs. Activated TLR4 recruits the ER stress kinase IRE1α to splice XBP1 mRNA, generating active XBP1s. XBP1s then binds promoters of proinflammatory genes (such as IL-6 and IL-8) and sustains cytokine production during bacterial infection.102 Different exogenous ligands or endogenous danger signals (DAMPs) can activate distinct TFs, but they may also converge on the same TFs. In RNA sensing, RIG-I is licensed by K63-linked ubiquitylation, principally mediated by TRIM25 on its tandem CARDs and by Riplet (RNF135) on the C-terminal domain. This modification enables CARD engagement with MAVS at mitochondria and explosive prion-like polymerization of MAVS filaments. These supramolecular assemblies then recruit and activate TBK1/IKKε to phosphorylate IRF3/7, and they also engage the IKK complex to liberate NF-κB.103–106 Phosphorylation of the adaptors themselves acts as a feed-forward amplifier. For instance, TBK1-dependent phosphorylation of MAVS, STING, and TRIF is sufficient to enable robust IRF3 activation. This finding underscores that adaptors are not passive but are instead enzymatically tuned signalosomes, dynamic complexes that facilitate specific and efficient signal transduction.107 In DNA sensing, cGAS catalyzes 2′3′-cGAMP upon DNA binding. cGAMP engages STING to drive ER-to-Golgi trafficking, conformational unlocking, and a decisive palmitoylation step at Cys88/Cys91 in the trans-Golgi that licenses TBK1 docking and transactivation of IRF3, with parallel IKK activation fueling NF-κB.108–110 STAT proteins become activated by cytokine receptor-associated Janus kinase (JAK), leading to their dimerization, nuclear translocation, and subsequent DNA binding to regulate immune-related genes.111,112 HIF-α stabilization and nuclear localization under hypoxia result from inhibited activity of prolyl hydroxylases, driving transcription of genes essential for cellular adaptation to hypoxic conditions.113,114 Negative regulation of TFs Having outlined the mechanisms underlying positive regulation of transcription factor activation, the following section turns to negative regulatory pathways that prevent excessive or chronic inflammation and thereby protect host tissues. PTMs remain one of the major mechanisms mediating the negative (inhibitory) regulation of transcription factor activation. Regulation of IRF3 involves SUMOylation, which dampens IFN-β transcription upon viral infection.115 For NF-κB, PIAS3-mediated SUMOylation of RelA/p65 represses κB-dependent transcription, consistent with classic demonstrations that SUMO-1 conjugation limits AP-1 (c-Fos/c-Jun) activity.116,117 NF-κB p65 acetylation at Lys310 by p300 enhances its transcriptional activity, whereas recruitment of HDAC3 deacetylates p65 and promotes histone deacetylation at κB sites to repress gene expression.118,119 The A20 (TNFAIP3) deubiquitinase removes K63/M1 chains to extinguish receptor-proximal scaffolds and is indispensable for restraining inflammation in vivo. PP1 dephosphorylates RIG-I/MDA5 to reset RNA sensing, and phosphatases throughout TLR cascades (such as DUSPs and PP2A) tune the MAPK, IKK, and IRF modules.120–122 Metabolites act as endogenous brakes on innate immune transcription factors by rewiring signaling nodes that converge on NF-κB, IRFs, STATs and others. A leading example is itaconate and its derivatives. 4-Octyl-itaconate (4-OI), a chemically esterified derivative of itaconate, acts by directly alkylating STING at Cys91 to prevent its palmitoylation, thereby inhibiting TBK1-IRF3 activation and subsequent type I IFN transcription.123 Additionally, 4-OI exerts anti-inflammatory functions by activating the NRF2 pathway, leading to the suppression of IL-6 and IL-12p40 secretion.124 Microbiota-derived short-chain fatty acids (such as butyrate) weaken NF-κB by HDAC inhibition, reducing p65 nuclear import and the expression of proinflammatory mediators in macrophages.125 In summary, various substances both in vivo and in vitro primarily regulate the transcriptional process through mechanisms centered on the activation of transcription factors. Epigenetic regulation Upon sensing pathogens or danger signals, innate immune responses rapidly induce host defense gene programs, whose execution is tightly orchestrated by epigenetic modifications. Epigenetics refers to heritable changes in gene activity that do not involve alterations to the DNA sequence but are instead mediated by DNA methylation, histone modifications, nucleosome positioning, higher-order chromatin architecture, RNA-based mechanisms and epigenetic factors (Fig. 3a–d). In innate immunity, epigenetic mechanisms endow innate immune cells with the ability to switch quickly and reversibly between quiescent, activated, tolerized, and trained states, thereby fine-tuning host defense while limiting immunopathology.126 This section dissects the molecular machinery and functional outcomes of these mechanisms in innate immunity. Major epigenetic modifications in innate immunity. a DNA methyltransferases catalyze DNA methylation predominantly at CpG dinucleotides, leading to transcriptional repression. Active DNA demethylation, mediated by TET2, removes methyl groups, thereby alleviating transcriptional constraints and facilitating the expression of genes involved in innate immune responses. b Histone modifications such as methylation and acetylation involve enzyme-mediated covalent alterations, particularly at the amino-terminal tails of histones H3 and H4. These modifications contribute to chromatin remodeling and accessibility, either activating or repressing gene transcription. c Chromatin remodeling primarily involves the regulation of nucleosomal histones through processes such as histone sliding, ejection, replacement, and nucleosome loading. These processes are catalyzed by distinct enzyme complexes that promote DNA unwinding, expose transcriptional start sites, and remove steric hindrance caused by histones, thereby enhancing chromatin accessibility and facilitating transcription. d The epitranscriptome refers to the collection of all chemical modifications on RNA that do not alter the nucleotide sequence but profoundly influence RNA fate and function. This rapidly expanding field has been most extensively studied in mRNA, with well-characterized modifications including m⁶A, Ψ, m¹A, m⁵C, m⁷G, ac⁴C, Nm, and A-to-I editing. These modifications influence mRNA splicing, stability, and translational efficiency. Additionally, modifications of other RNA species, such as tRNA and rRNA, also modulate their functions and play regulatory roles in innate immune responses. This figure was created with BioRender (http://biorender.com/) DNA methylation DNA methylation involves the addition of methyl groups to the fifth carbon of cytosine residues (5-methylcytosine, 5mC), predominantly occurring at CpG dinucleotides. This modification generally suppresses gene transcription by hindering transcription factor binding or recruiting methyl-binding domain proteins that mediate chromatin compaction.127 DNA methylation is dynamically regulated by DNA methyltransferases (DNMT1, DNMT3A/B) and ten-eleven translocation (TET) enzymes that catalyze DNA demethylation. This regulatory axis profoundly affects innate immune gene expression. For example, upon antiviral signaling, a specific CpG site methylation in the Ifnb promoter prevents the recruitment of TFs such as IRF3, thus repressing type I IFN expression.128 DNA methylation is not a unidirectional regulatory process but rather operates in a dynamic and reversible manner. Active DNA demethylation mediated by TET2 is vital for myeloid lineage differentiation, enabling macrophages and DCs to rapidly upregulate inflammatory genes in response to pathogens.127 In human DCs, live Mycobacterium tuberculosis infection triggers active, replication-independent demethylation at thousands of distal enhancers in step with increases in chromatin accessibility and activation marks, illustrating that CpG methylation can be dynamically rewritten in nondividing innate cells.129 Epigenetic remodeling through DNA methylation is also implicated in trained immunity. Neonatal Bacillus Calmette-Guérin (BCG) vaccination, a live attenuated strain of Mycobacterium bovis, imprints persistent DNA methylation changes in monocytes, influencing genes associated with antiviral pathways and strengthening subsequent immune responses.130 Furthermore, microbial infections induce genome-wide DNA methylation shifts in host immune cells, establishing a lasting epigenetic signature that shapes future responses to similar stimuli.131 Thus, DNA methylation acts as a stable yet adaptable epigenetic regulator that modulates innate immune cell identity, differentiation, and functional memory. Histone methylation Histone methylation occurs at lysine or arginine residues and can either activate or repress gene transcription depending on the site and methylation state. Common activating marks include H3K4me3, whereas H3K27me3 and H3K9me3 generally repress transcription.132 These modifications are governed by histone methyltransferases (such as the SET1/MLL family for H3K4 and EZH2 for H3K27) and demethylases (such as KDMs of the JmjC family). In innate immunity, histone methylation shapes both acute inflammatory transcription and innate immune memory. Following TLR or NF-κB activation, H3K4 methyltransferase complexes can be recruited to inflammatory gene loci, promoting H3K4 methylation and facilitating cytokine transcription.133 Additionally, persistent H3K4me1 and H3K4me3 marks at enhancers and promoters underpin trained immunity, enabling stronger secondary inflammatory responses upon re-exposure.130 This robust immune response can also exert detrimental effects. A prime example is myocardial infarction, where the induction of trained immunity in monocytes accelerates atherosclerosis.134 The specific modulation of H3K27 methylation further determines macrophage polarization. Demethylation of H3K27me3 via JMJD3 following TLR activation enhances the expression of key inflammatory genes such as IL-6, while sustained H3K27me3 enforces endotoxin tolerance.135–137 Histone methylation dynamics are also closely linked to cellular metabolism, where metabolites such as α-ketoglutarate or succinate influence histone methyltransferase and demethylase activities, thus impacting macrophage immune function and polarization.138–141 Therefore, histone methylation constitutes a critical epigenetic framework integrating innate immune signals, metabolic status, and inflammatory memory. Histone acetylation Histone acetylation represents a critical epigenetic modification involving the addition of acetyl groups to lysine residues on histone tails, which neutralizes their positive charges and subsequently relaxes chromatin, enabling gene transcription. The equilibrium of histone acetylation is dynamically maintained by histone acetyltransferase, including p300/CBP, and histone deacetylases such as class I/II histone deacetylases and sirtuins.142 In innate immune responses, histone acetylation rapidly translates extracellular signals, such as PAMPs, into transcriptional activation. For instance, TLR stimulation or IFN-γ signaling promotes recruitment of CBP/p300 to key inflammatory loci (such as TNFα and IL-6), driving histone acetylation and subsequent cytokine expression.143 Moreover, trained immunity also depends heavily on persistent histone acetylation at pro-inflammatory gene enhancers, resulting in heightened responses upon restimulation. Neonatal BCG vaccination triggers lasting H3K27 acetylation changes in circulating monocytes, enhancing their long-term innate response capacity.144,145 Acetyl-CoA abundance, generated via glycolysis, directly modulates histone acetyltransferase activity, linking metabolic flux to epigenetic-driven inflammation. Microbiota-derived acetate serves as an acetyl-CoA precursor, activating Tip60-mediated histone acetylation in gut macrophages and strengthening innate defense.146 A recent study further demonstrated that in diabetic conditions, neutrophils undergo trained immunity characterized by metabolic reprogramming that promotes acetyl-CoA accumulation, which in turn drives histone H3 and H4 acetylation, thereby priming these cells for enhanced effector functions.147 Histone lactylation Histone lactylation, particularly H3K18la, has emerged as a cornerstone of innate immune memory. In BCG-vaccinated individuals, monocytes exhibit sustained H3K18la enrichment at enhancers of IL1B and CXCL9 for up to 90 days post-vaccination. This modification integrates glycolytic flux with chromatin remodeling. BCG activates mTOR-HIF-1α signaling, upregulating lactate dehydrogenase A (LDHA) and generating lactate, which recruits p300/CBP to deposit H3K18la at immune gene loci. Genetic variants in LDHA or EP300 diminish cytokine responses in human cohorts, underscoring lactylation’s nonredundant role in trained immunity. H3K18la stabilizes open chromatin conformations at topologically associating domains, colocalizing with CTCF and the lncRNA AMANZI to facilitate chromatin looping for rapid IL-1β reactivation upon secondary challenges.148,149 Additional epigenetic regulatory layers have been uncovered in recent years, including chromatin remodeling, RNA modifications, and cGAS demethylation, among others (Fig. 3c).150,151 Epitranscriptomic RNA methylation (such as m6A on mRNA) will be discussed in subsequent sections. Together, epigenetic modifications, ranging from histone lactylation to DNA methylation, constitute a versatile regulatory layer that tailors innate immune responses to metabolic, environmental and pathogenic cues. mRNA alternative splicing and stability The innate immune system relies on rapid and precisely orchestrated gene expression programs to respond to pathogenic microorganisms or danger signals while avoiding excessive inflammation. The maturation of eukaryotic RNA into functional mRNA, followed by its translation into protein, involves multiple processing steps, among which RNA splicing and mRNA stability play crucial roles. Beyond transcriptional control, posttranscriptional regulation through splicing and stability serves as a critical layer for regulating immune responses. This section focuses on the roles of alternative splicing and mRNA stability in innate immunity. mRNA alternative splicing in innate immunity RNA splicing is the process by which the primary transcript (pre-mRNA) is processed to remove introns and ligate exons, yielding mature mRNA capable of encoding proteins. However, this process does not invariably yield a single product. Some mRNAs may retain introns. Pre-mRNAs can be processed into noncoding RNAs. Eukaryotic pre-mRNAs often undergo alternative splicing to generate distinct mature transcripts. The mechanisms and regulation of RNA splicing are highly complex. However, a detailed discussion of these mechanisms lies beyond the scope of this section. For a comprehensive discussion of such mechanistic insights, we refer readers to several excellent recent reviews.152,153 This section will instead focus on elucidating the functional significance of mRNA alternative splicing in innate immunity. Alternative splicing (AS) broadens the innate immune proteome by generating protein isoforms with distinct or even opposing functions. Nearly all TLRs and key signaling intermediates exhibit multiple splice variants that modulate immune signaling. For example, the adaptor protein MyD88 exists as a full-length form and a shorter splice isoform, MyD88-S, which lacks the intermediate domain. MyD88-S, induced upon LPS stimulation, functions as a dominant-negative regulator of TLR signaling by preventing interleukin-1 receptor-associated kinase 4 (IRAK4) recruitment and thus dampening NF-κB activation.154,155 In the RLR pathway, a bicistronic MAVS transcript yields miniMAVS, a shorter isoform that modulates full-length MAVS signaling output and thus tunes type I IFN production.156 Additionally, splice decisions can hard-wire protein localization and thereby ensure compartmentalized control of signaling cascades during innate immune responses. It is well established that in its resting state, the STING molecule resides in the ER. Upon stimulation by cytosolic DNA, it translocates to the Golgi apparatus where it becomes activated, subsequently initiating downstream signaling pathways. An alternatively spliced pmSTING isoform localizes to the plasma membrane and directly senses extracellular cGAMP to trigger TBK1-IRF3, revealing compartmental logic in DNA sensing.157 Recent research has identified two different splicing isoforms of Uhrf2 in Miichthys miiuy, nuclear Uhrf2-α and cytoplasmic Uhrf2-β, both of which inhibit the activation of the IRF3 and NF-κB signaling pathways.158 Although the mechanisms underlying the differential localization of these two isoforms remain unclear, these isoforms may possess additional as yet unidentified functions. Moreover, many splice variants behave as on/off or rheostat-like switches that are inducible by infection or cytokines. MyD88S accumulation during endotoxin exposure dampens NF-κB output and contributes to tolerance, thereby functionally switching the TLR pathway toward restraint.154 In the TLR cascade, the human-specific IRAK1c splice isoform (exon-11 skipping) lacks kinase activity yet competes for complex assembly, thereby reducing downstream signaling. This decoy kinase behavior exemplifies a splicing-encoded brake. AS frequently introduces premature termination codons that target transcripts to nonsense-mediated mRNA decay (NMD), creating regulated unproductive splicing and translation circuits that set innate immune thresholds. The most compelling human evidence connecting OAS1 splicing and AS-NMD to COVID-19 outcomes comes from the chr12q24.13 locus. While the risk haplotype (including rs10774671-A and rs1131454-A) reduces OAS1 protein via allele-specific splicing coupled to NMD and thus increases hospitalization risk, genetic programs that favor the p46 isoform (and consequently higher OAS1 levels) are protective.159 More broadly, pathway-level surveys indicate that numerous TLR and nucleic acid-sensing genes harbor AS-NMD events, positioning NMD as a pervasive posttranscriptional governor of innate responses.160 Environmental and physiological cues also influence AS patterns. Los et al. found that modest increases in body temperature enhance the expression of antiviral genes through reduced nonsense-mediated decay of STAT2 mRNA, a process governed by temperature-sensitive splicing events.161 Collectively, these examples illustrate that AS is a dynamic mechanism for tuning the intensity, specificity, and resolution of innate immune responses. mRNA stability in innate immunity mRNA stability in innate immunity is fundamentally determined by key cis-acting regulatory elements. The 5′m⁷G cap structure protects against exonucleolytic degradation (such as by XRN1) and facilitates nuclear export and translation initiation.162 Conversely, decapping enzymes (DCP1/2) remove this cap to initiate mRNA decay pathways. The 3’poly(A) tail, bound by poly(A)-binding protein, forms a closed-loop complex with eIF4G to enhance translation and block 3’→5’ exonuclease access. Deadenylation by CCR4-NOT and PAN2-PAN3 complexes shortens the poly(A) tail, triggering decapping or exosome-mediated decay.163 The 3’ untranslated region (3’UTR) harbors instability elements such as AU-rich elements and GU-rich elements, which recruit decay factors or RNA-binding proteins (RBPs) to regulate mRNA half-lives.164,165 These core elements and their associated RBPs thus establish a dynamic balance that dictates transcript half-life, enabling rapid adjustment of innate immune gene expression. RBPs are pivotal trans-factors interpreting cis-elements to modulate mRNA stability in innate immune responses. Tristetraprolin (TTP), induced promptly upon pathogen encounter, binds AU-rich elements of key pro-inflammatory cytokine mRNAs and promotes degradation by recruiting decay complexes.166 A recent study showed that SP140 represses transcription of the RESIST gene, which encodes a protein that stabilizes Ifnb1 mRNA by blocking TTP and CCR4-NOT-mediated deadenylation.167 Conversely, HuR binds to overlapping ARE regions and reinforces transcript stability. It undergoes posttranslational modifications, such as phosphorylation or ubiquitination, in response to signaling cascades. For example, phosphorylation may facilitate its nucleocytoplasmic translocation, which enables stabilization of inflammatory transcripts in the cytosol.168,169 Indeed, PTMs further refine RBP activity. For example, p38 MAPK phosphorylates TTP to inhibit its decay-promoting function, permitting TNF-α accumulation.170 TLR signaling activates the IKK complex, which phosphorylates Regnase-1 and leads to its ubiquitin-proteasome-dependent degradation, thereby relieving suppression of IL-6 mRNA and amplifying inflammation.171 These pathways enable immune cells to calibrate cytokine production within minutes of PAMP or DAMP sensing, while feedback loops prevent uncontrolled responses. Over 100 types of RNA chemical modifications have been identified to date. However, the repertoire of modifications present in mRNA remains relatively limited, including N6-methyladenosine (m6A), pseudouridine (Ψ), N1-methyladenosine (m1A), 5-methylcytosine (5mC), N7-methylguanosine (m7G), N4-acetylcytidine (ac4C), 2’-O-methylation (2′OMe), A-to-I editing and others (Fig. 3d). The types of modifications that influence mRNA stability include m6A, 5mC, Ψ, ac4C, and A-to-I editing.172–177 Among these modifications, m6A is the most abundant type in eukaryotic mRNA, occurring in approximately 25% of mammalian mRNAs.178,179 Overall, m6A modification of mRNA promotes the decay of methylated transcripts. However, m6A exerts bidirectional control over innate immune output by targeting both effector and inhibitory transcripts for decay. On the one hand, METTL3/14-installed m6A marks on IFNB1 recruit YTHDF2 to accelerate IFN-β mRNA turnover, attenuating antiviral signaling and ISG induction in infected cells. On the other hand, m6A-guided YTHDF2 promotes the decay of brake genes, with the MAPK phosphatase DUSP1 as a representative example. This degradation removes negative feedback, thereby sustaining p38/JNK activity and amplifying proinflammatory cytokine expression during LPS challenge and infection.180,181 Thus, by degrading either immune genes or their repressors, the m⁶A pathway finely tunes the net amplitude and duration of innate responses. For further discussion of additional mRNA chemical modifications influencing transcript stability, readers are referred to the references cited above. Recently, discovered noncoding RNAs, specifically microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), also play a critical role in regulating mRNA stability. MicroRNAs (miRNAs) bind the 3′UTRs of target mRNAs to direct Argonaute (AGO)-mediated transcript silencing or cleavage. We previously demonstrated that microRNA-302b enhances host antibacterial defense by modulating inflammatory responses through feedback regulation of TLR/IRAK4 circuits. Notably, we also found that Pseudomonas aeruginosa infection exacerbates inflammation by suppressing miR-301b, which leads to impaired c-Myb-mediated immune activation and leukocyte infiltration.182,183 miRNA let-7 is downregulated in macrophages upon microbial stimulation, relieving suppression of IL-6/IL-10 and enhancing TLR4 signaling.184,185 Both circRNAs and lncRNAs can function as miRNA sponges, thereby alleviating miRNA-mediated degradation of target mRNAs. These subjects have been extensively reviewed in the literature and will not be discussed further here. Metabolic reprogramming in innate immunity Metabolites participate directly in innate immune regulation rather than merely representing downstream outcomes. Innate immune cells dynamically rewire their metabolism upon activation, a concept that has emerged over the past decade as a frontier in immunology.186,187 Early studies noted clear differences between quiescent and activated immune cells in their metabolic pathways.188,189 In particular, innate myeloid cells such as macrophages and DCs undergo profound metabolic remodeling in response to microbial signals, which in turn shapes their functional phenotype. Proinflammatory activation (M1 polarization) is typically associated with a metabolic shift to rapid glycolysis and a truncated tricarboxylic acid (TCA) cycle, whereas anti-inflammatory or tissue-repair activation (M2 polarization) relies on oxidative metabolism and fatty acid oxidation (FAO).190–192 These metabolic programs are not merely consequences of activation but are causally linked to effector functions. Metabolites and metabolic enzymes act as signaling intermediates that modulate cytokine production, gene expression, and cell survival (Fig. 4).193,194 Indeed, the intimate crosstalk between metabolic pathways and innate immune signaling has become a defining feature of innate immunity’s regulatory complexity. Major metabolic controls in innate immune responses. After entering cells, glucose is phosphorylated by hexokinases to glucose-6-phosphate (G-6-P). G-6-P can be diverted into the pentose phosphate pathway (PPP) to generate ribose-5-phosphate and abundant nicotinamide adenine dinucleotide phosphate (NADPH). The NADPH pool tunes kynurenine 3-monooxygenase (KMO) activity, thereby modulating the production of 3-HK, an immunoregulatory metabolite. During glycolysis, G-6-P is converted stepwise to pyruvate. Under hypoxia, pyruvate is reduced to lactate, which shapes innate immune signaling. Under normoxia, pyruvate is converted to acetyl-coenzyme A (acetyl-CoA) and condenses with oxaloacetate via citrate synthase to form citrate, entering the TCA cycle. Fatty acids liberated from complex lipids undergo β-oxidation to yield acetyl-CoA that feeds the TCA cycle, whose intermediates participate in innate immune regulation. Cholesterol esterification sequesters cholesterol in lipid droplets, a process with immunomodulatory consequences. Additionally, cholesterol can be hydroxylated by cholesterol 25-hydroxylase to 25-hydroxycholesterol, a key regulator of immune homeostasis. Several amino acids, including leucine, isoleucine, lysine, and tryptophan, are catabolized through decarboxylation and oxidation to acetyl-CoA, whereas alanine, serine, cysteine, and a fraction of tryptophan first generate pyruvate, which is converted to acetyl-CoA by the pyruvate dehydrogenase complex to enter the TCA cycle. In parallel, glutamate, cysteine, and glycine are precursors of glutathione, whose cycling between reduced GSH and oxidized glutathione forms detoxifies ROS and maintains intracellular redox balance. Glutaminolysis directs glutamine into glutamate and ultimately α-ketoglutarate, which not only fuels the TCA cycle but also promotes M2 macrophage polarization. This figure was created with BioRender (http://biorender.com/) Glycolysis One hallmark of innate immune activation is the induction of glycolysis even in the presence of oxygen (aerobic glycolysis), reminiscent of the Warburg effect classically observed in tumors. LPS-stimulated macrophages rapidly upregulate glucose uptake and flux through glycolysis to meet the energetic and biosynthetic demands of inflammation.195,196 This glycolytic switch is accompanied by a block in the TCA cycle at isocitrate dehydrogenase, leading to the accumulation of succinate.197,198 Succinate acts as an inflammatory signal that stabilizes hypoxia-inducible factor 1α (HIF-1α) and drives the production of interleukin-1β (IL-1β) in LPS-activated macrophages.193 Concurrently, pyruvate kinase M2 in these cells adopts a dimeric, nucleus-translocating form that coactivates HIF-1α, further amplifying glycolytic gene expression and IL-1β transcription.194 Inhibition of pyruvate kinase M2 or HIF-1α abrogates this aerobic glycolysis and the associated cytokine production, underscoring the importance of glycolysis in pro-inflammatory responses.194 Notably, the induction of glycolysis is also a feature of trained immunity, a form of innate immune memory. Brief exposure to β-glucan or BCG vaccination induces epigenetic and metabolic reprogramming that enhances responsiveness to secondary challenges, a phenotype underpinned by sustained increases in glycolytic flux.196,199 This training effect depends on the mTOR-HIF-1α pathway. Pharmacological activation of AMP-activated protein kinase (AMPK) or treatment with glycolysis inhibitors such as 2-deoxyglucose can inhibit trained immunity.199 Additionally, chronic hyperglycemia in diabetes can induce a trained-immunity-like program in macrophages via glycolytic and epigenetic reprogramming, which contributes to inflammatory complications such as atherosclerosis.195 These examples illustrate how glycolysis is an important driver of innate immune activation and memory. Lipid metabolism Beyond glucose, lipid metabolism, which encompasses FAO, de novo lipogenesis, cholesterol biosynthesis, and bioactive lipid mediator production, plays multifaceted roles in innate immunity. Activated macrophages reprogram lipid metabolism in stimulus-specific ways to support their functional needs.200 In inflammatory macrophages (M1), de novo fatty acid synthesis is upregulated to expand ER and plasma membrane compartments necessary for cytokine secretion and inflammasome assembly. Excess citrate is funneled via ACLY and acetyl-CoA carboxylase (ACC) into fatty acid production, which supplies membranes for rapid cell growth and yields inflammatory mediators from arachidonic acid.198,200 The bioactive lipid mediators derived from arachidonic acid, which include prostaglandins, leukotrienes, and specialized proresolving mediators, fine-tune the inflammatory cascade. The balance between pro-inflammatory PGE2 and anti-inflammatory lipoxin A4 regulates neutrophil recruitment and macrophage efferocytosis, thereby dictating the resolution or persistence of inflammation.201 In contrast, alternatively activated macrophages and certain other innate cells display enhanced lipid handling, oxidative metabolism, and FAO, features associated with anti-inflammatory and tissue-repair functions.188,202 IL-4-induced alternative activation has been linked to mitochondrial β-oxidation and regulators such as PGC-1β and AMPK, but the causal requirement for mitochondrial FAO remains debated.188,203 Notably, etomoxir can impair M2-like polarization through FAO-independent mechanisms, including disruption of CoA homeostasis.204,205 Lipid catabolism also supports long-lived functional states in certain innate cells. For instance, autophagy-driven lipid degradation provides fatty acids to fuel the oxidative phosphorylation required for neutrophil differentiation and longevity.206 On the other hand, dysregulated lipid uptake or storage can lead to foam cell formation and NLRP3 inflammasome activation in macrophages, which is a key event in atherogenesis when exposed to excess cholesterol crystals or fatty acids.207–209 Indeed, innate immune cells sense free fatty acids as danger signals. Saturated fatty acids can engage TLRs and promote inflammasome-mediated IL-1β release, linking metabolic syndrome to innate inflammation.191 Notably, the mevalonate/cholesterol synthesis pathway is required for trained immunity, and blocking cholesterol synthesis dampens β-glucan-induced training of monocytes, indicating that endogenous lipid synthesis pathways contribute to the epigenetic reprogramming of trained innate cells.210,211 In summary, lipid metabolism has dual faces in innate immunity, providing fuel for oxidative metabolism in restorative states and supplying building blocks and signals for inflammatory responses in aggressive states. Amino acid metabolism Amino acid metabolism is another crucial layer of innate immune regulation. Innate immune cells utilize amino acids not only for protein synthesis but also as substrates for energy and as precursors for regulatory metabolites.212 For example, glutamine is heavily consumed by activated macrophages and DCs, which feeds the TCA cycle (via α-ketoglutarate) to sustain the production of succinate and other metabolites that drive inflammatory gene programs.193,210,213 Glutaminolysis-derived α-ketoglutarate plays a central role in orchestrating alternative (M2) macrophage activation by engaging FAO and facilitating Jmjd3-dependent epigenetic reprogramming of M2 genes.139 Glutaminolysis is indispensable for trained immunity. Inhibition of glutaminase abrogates β-glucan-induced training and reduces pro-inflammatory cytokine output.210 Arginine metabolism bifurcates into either the nitric oxide pathway via inducible nitric oxide synthase or the ornithine/polyamine pathway via arginase-1, with profound effects on immune function. Classically activated macrophages channel arginine into nitric oxide, a reactive radical that contributes to pathogen killing and amplifies inflammation, whereas alternatively activated macrophages upregulate arginase-1 to produce ornithine and polyamines, promoting cell proliferation and tissue repair.214–217 The balance of these arginine pathways helps define the M1 vs M2 polarization states. Indeed, arginase-1 is now recognized as a key metabolic regulator in certain innate cells, such as group 2 innate lymphoid cells (ILC2s), where arginase-driven polyamine synthesis supports proliferation and effector functions.218 Tryptophan catabolism is another immunoregulatory mechanism in innate immunity, predominantly through the enzyme indoleamine 2,3-dioxygenase (IDO) expressed by DCs, macrophages, and other cells. IDO-mediated tryptophan catabolism limits local tryptophan availability and generates kynurenine pathway metabolites, particularly kynurenine, which can activate AhR-dependent immunoregulatory programs.219–221 Through these mechanisms, the IDO-kynurenine-AhR axis contributes to peripheral tolerance and restrains excessive inflammatory responses.222 This pathway is often hijacked in cancer and chronic infections to suppress immune responses. In innate cells, upregulation of IDO can enforce an anti-inflammatory state (sometimes termed endotoxin tolerance in macrophages), whereas blockade of IDO activity has been shown to boost antimicrobial and antitumor immunity.223 Additionally, amino acids such as serine and glycine feed one-carbon metabolism for nucleotide synthesis and methylation reactions, while a deficiency in these pathways can limit cell proliferation and alter epigenetic marks during macrophage activation.223,224 Cysteine availability controls glutathione-dependent redox buffering in innate cells, thereby influencing ROS signaling and inflammasome activation.225 In summary, amino acid availability and catabolism significantly shape innate immune cell function by controlling substrate-level supply for energy and biosynthesis as well as producing metabolic signals that modulate immunity. TCA cycle The TCA cycle is located at the crossroads of carbohydrate, lipid, and amino acid metabolism. It supplies not only ATP and reducing equivalents but also key intermediates such as citrate, α-ketoglutarate, succinate, fumarate, and itaconate. These intermediates serve as biosynthetic precursors, epigenetic modifiers, and signaling molecules. In innate immune cells, as noted, remodeling of the TCA cycle during activation creates breaks that lead to succinate accumulation, stabilizing HIF-1α and promoting proinflammatory cytokine production, while IRG1-driven itaconate generation tempers inflammation and supports antimicrobial defense. However, the same metabolite may play different roles in different tissues or cells. Contrary to its traditionally recognized anti-inflammatory effects, itaconate promotes LPS-induced pro-inflammatory cytokine production and NLRP3 inflammasome activation in tissue-resident alveolar macrophages (AMs).226 Exported citrate fuels fatty acid synthesis and histone acetylation of inflammatory genes, whereas glutamine-derived α-ketoglutarate and fumarate modulate histone demethylases and DNA methylation to influence macrophage polarization. Thus, the dynamic flux of the TCA cycle integrates metabolic and immune cues, orchestrating both the effector and resolution phases of innate immunity. In addition to directly participating in the regulation of innate immune response processes, accumulating research evidence in recent years has revealed that an increasing number of metabolites within the TCA cycle, as well as those indirectly involved in the TCA cycle, can serve as posttranslational modification (PTM) donors, thereby indirectly influencing innate immune responses. For instance, a recent study reported that pyruvate induces STAT1 protein pyruvylation, thereby inhibiting interferon signaling.227 Further extensive investigation is required to elucidate the regulatory roles of additional TCA cycle intermediates in innate immunity. Innate immunity in health and diseases Innate immunity is a central determinant of human health and disease. This section first outlines how innate immune programs sustain organismal homeostasis and host fitness and then discusses how physiological variation across sex and age shapes the baseline architecture and functional output of innate immunity in health. We next summarize disorders in which core innate immune pathways, molecular components or effector cells serve as the primary or direct drivers of pathogenesis. Finally, this framework is extended to a broader disease landscape, and three canonical modes by which dysregulated innate immunity participates in, amplifies, or accelerates diverse pathological processes are highlighted. Innate immunity in health homeostasis Innate immunity represents the primary defensive arm of the immune system and is indispensable for sustaining homeostasis. The first layer of defense is established by mucosal and cutaneous barriers, which effectively block the majority of invading microbes. Once these barriers are compromised, soluble immune effectors, including cytokines and complements, alongside innate immune sensors, form a rapid protective shield. Antigen-presenting cells, particularly DCs, subsequently connect innate and adaptive immunity, ensuring coordinated host defense. Here, we briefly summarize how innate immunity maintains homeostasis through its diverse components (Fig. 5). Innate immunity in maintaining host health. Innate immunity constitutes the first and second lines of host defense against bacterial, fungal, and viral invasion, while simultaneously bridging to adaptive immunity. The first line of defense is provided by mucosal and cutaneous barriers, encompassing both physical and chemical components. Physical barriers, such as the gastrointestinal epithelium and mucus layers, mechanically block pathogen entry. Chemical barriers include dedicated immune effectors such as defensins and lysozyme, as well as auxiliary antimicrobial factors such as digestive fluids. The second line of defense involves immune effector proteins and innate immune cells. Soluble effectors such as complement components and cytokines exert direct microbicidal activity and orchestrate immune cell recruitment. Effector cells, including neutrophils, NK cells, and macrophages, mediate rapid pathogen clearance through direct cytotoxicity and phagocytosis. ILC3s maintain intestinal barrier function through IL-22, whereas LTi cells induce and sustain gut-associated lymphoid tissues. Finally, antigen-presenting cells, particularly DCs, present antigens to T and B lymphocytes, thereby linking innate and adaptive immunity. This figure was created with BioRender (http://biorender.com/) First-line defenses formed by skin and mucosal barriers Innate immunity constitutes a critical component of host homeostasis, with one of its central functions being the defense against microbial invasion. As the first line of immune defense, innate immunity provides immediate and nonspecific protection through two primary types of barriers. Physical barriers are formed by the skin and epithelial surfaces, which block pathogen ingress through tight junctions, cornification and mucociliary clearance. In parallel, chemical barriers composed of lysozyme, defensins, and other antimicrobial peptides mediate broad-spectrum microbicidal effects at mucosal and cutaneous surfaces.228 The following discussion delineates how innate immune mechanisms maintain tissue homeostasis and coordinate early host defense responses against bacterial, viral, and fungal infections. The physical barriers The physical barriers comprise the epithelial layers of the skin and the mucosal tissues connected to the body’s openings. To resist microbial invasion, epithelia at distinct sites develop specialized architectures, such as skin and mucosa. The skin comprises a keratinizing stratified squamous epithelium. At the surface, the keratinized epithelium, together with surface secretions, forms a laminated “brick-and-mortar” barrier, while tight junctions at the basal aspect seal intercellular spaces.229 Continuous proliferation in the basal layer drives rapid turnover and desquamation, mechanically removing adherent microbes.229 The mucosa comprises a ciliated epithelium interspersed with goblet cells and overlaid by a mucus layer, which together establish an effective barrier. In addition to tight epithelial barriers, mucosal surfaces eliminate microbes through mucus entrapment and coordinated physical clearance mechanisms. In the lung, coordinated ciliary beating propels mucus to prevent microbial colonization, while coughing and sneezing provide high-shear clearance of entrapped particles and pathogens.230 Chemical barriers Chemical barriers comprise host-defense peptides and proteins, together with physiological secretions that possess ancillary antimicrobial activity. Host-defense molecules span a broad biophysical spectrum from short peptides of 10 kDa to complex glycoproteins and restrict microbial invasion through complementary mechanisms, including membrane permeabilization, enzymatic degradation of cell-wall scaffolds, and sequestration of limiting nutrients. Defensins are short, cationic, amphipathic peptides that rapidly permeabilize microbial membranes, killing bacteria, fungi, and many enveloped viruses within minutes.231 Lysozyme is a canonical muramidase that is abundant in tears and saliva and is secreted by Paneth cells and phagocytes. It hydrolyzes the β-glycosidic linkage between N-acetylglucosamine and N-acetylmuramic acid in bacterial peptidoglycan, creating focal defects that expose the cytoplasmic membrane to additional stresses.232 Lactoferrin is a multifunctional iron-binding glycoprotein that both deprives microbes of Fe³⁺ and exerts direct membrane-active and immunomodulatory effects. By chelating iron at mucosal surfaces, lactoferrin curtails bacterial proliferation, shapes local cytokine programs, and modulates oxidative stress.233 Physiological secretions such as pulmonary surfactant collectins and gastrointestinal fluids play essential roles in surface tension regulation and digestion. These secretions incidentally generate antimicrobial environments that restrict microbial colonization. Pulmonary surfactant proteins A and D are collagen-containing collectins that bind carbohydrate and lipid motifs on microbes, agglutinate pathogens, opsonize AMs, and calibrate inflammatory outputs.234 These dual-function molecules maintain alveolar homeostasis while enhancing early pathogen clearance. For gastrointestinal fluids, the gastrointestinal tract produces a complex repertoire of physiological secretions, including gastric acid, bile salts and digestive enzymes, that not only mediate nutrient digestion but also exert potent antimicrobial effects.235 Second-line defenses involving soluble effectors and innate immune cells Despite robust barrier immunity at the skin and mucosal interfaces, these defenses can be breached by trauma or arthropod bites, enabling pathogens to traverse the epithelium. Some microbes further subvert the barrier by infecting epithelial cells and penetrating this primary line of defense. Once within tissues or the circulation, a second tier of innate protection is mobilized, comprising innate immune cells that act to eliminate invading organisms. Neutrophils Neutrophils deploy multiple pattern-recognition systems to detect invading microbes. Calprotectin, a heterodimer formed by S100A8 and S100A9, represents one of the most abundant cytosolic proteins in neutrophils, constituting up to 30–60% of cytosolic protein content.236 Upon neutrophil activation, calprotectin is rapidly released into the extracellular milieu, where it exerts potent antimicrobial and immunoamplificatory functions. By chelating essential transition metals, including Fe, Zn, and Mn, it suppresses pathogen metabolic fitness through nutritional immunity.237 Simultaneously, extracellular calprotectin functions as a DAMP, activating TLR4-dependent pathways to induce NF-κB-mediated transcription of pro-inflammatory cytokines and to promote leukocyte recruitment, thereby establishing a feed-forward inflammatory circuit.238 Functionally, neutrophils mediate host defense through three principal programs: phagocytosis, granule exocytosis (degranulation), and NET formation. Nonopsonic sensors such as Dectin-1 recognize fungal β-glucans, scavenger receptors bind diverse anionic ligands, and TLRs amplify antimicrobial programs.239 In parallel, opsonin receptors, including CR1/3/4 and collectin or C1q receptors, translate complement and lectin tagging into efficient phagocytosis. Once engaged, neutrophils rapidly engulf pathogens into phagosomes that fuse with lysosomal granules. Within these compartments, assembly of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase generates ROS, while myeloperoxidase converts hydrogen peroxide to hypochlorite, and acidification activates proteases such as elastase and cathepsin G, together producing a highly microbicidal environment.240 In addition to phagocytosis, neutrophils mobilize their distinct granule populations. Primary (azurophilic) granules deliver MPO, defensins, and serine proteases, secondary granules provide lactoferrin and lipocalin-2, and tertiary granules release matrix metalloproteinases (MMPs).241 Their fusion with phagosomes or the plasma membrane ensures targeted delivery of antimicrobial effectors, matrix remodeling enzymes, and receptors needed for sustained clearance.241 A further antimicrobial strategy is the release of NETs. NETs are released through a process requiring ROS, MPO, elastase, and PAD4-mediated histone citrullination that drives chromatin decondensation and expulsion.242 These web-like structures entrap bacteria and fungi, concentrate antimicrobial proteins, and restrict dissemination but also act as DAMPs that amplify local inflammation. Monocytes/macrophages Macrophages deploy a diverse repertoire of PRRs to detect bacteria, fungi and viruses. Surface and endosomal sensors include TLR4-MD-2-CD14 for LPS, TLR2 heterodimers for lipoproteins and peptidoglycan, TLR5 for flagellin, and TLR3/7/8/9 for nucleic acids, while cytosolic NOD1/2, RIG-I, MDA5, and the cGAS-STING axis extend surveillance to intracellular pathogens.16,243 C-type lectins such as Dectin-1 and the mannose receptor promote fungal recognition and uptake.16 Upon microbial sensing, PRR signaling through NF-κB, IRFs, and STATs drives classical polarization toward an M1-like phenotype.244 Activated macrophages secrete proinflammatory cytokines, including TNF, IL-1β, IL-6, and type I IFNs, as well as chemokines, such as CCL2 and CXCL8.244 In parallel, macrophages eliminate microbes through phagocytosis and microbicidal effector mechanisms.245 Nonopsonic uptake via CLRs and scavenger receptors complements opsonin-dependent phagocytosis through CR1/CR3 and Fc receptors. Mature phagosomes fuse with lysosomes, activating NOX2 to generate reactive oxygen and nitrogen species, while acidification releases proteases and antimicrobial peptides. Together, these programs integrate recognition, killing and cytokine orchestration, positioning macrophages as central effectors of innate host defense and modulators of adaptive immunity. Beyond the classical monocyte-derived macrophages described above, the innate immune system also comprises a diverse network of tissue-resident macrophages that originate primarily from embryonic progenitors (yolk sac and fetal liver) and maintain themselves through local self-renewal independent of circulating monocytes.246 These resident populations include microglia in the central nervous system, Kupffer cells in the liver, alveolar macrophages in the lung, Langerhans cells in the skin, and osteoclasts in bone and exhibit remarkable functional specialization tailored to their anatomical niches.247 Both intrinsic genetic background and local tissue-derived signals are considered central determinants of tissue-resident macrophage phenotype and function.248 This is particularly evident in the liver, where stellate cells, hepatocytes, and sinusoidal endothelial cells provide instructive signals that drive infiltrating monocytes to adopt Kupffer cell identity, indicating that tissue signals imprint tissue-resident macrophages with stable characteristics that distinguish them from newly recruited monocyte-derived macrophages.249 Innate lymphoid cells Innate lymphoid cells (ILCs) are a family of lymphocytes that, unlike adaptive T and B cells, do not express somatically rearranged antigen receptors.250 Despite this defining distinction, they arise from developmental pathways closely related to those of adaptive lymphocytes and retain the classical small, round morphology typical of most circulating lymphoid cells. Initially, ILCs were classified into three major groups according to their functions and the key transcription factors expressed at mature stages. Group 1 ILCs, comprising natural killer (NK) cells and ILC1s, are driven by T-bet and produce IFN-γ and TNF. Group 2 ILCs are defined by high GATA3 expression and secrete type 2 cytokines such as IL-4, IL-5 and IL-13. Group 3 ILCs depend on RORγt and are characterized by the production of IL-17 and/or IL-22, including ILC3s and lymphoid tissue inducer (LTi) cells.251 Recent progress in ILC developmental biology has favored a five-subset model of ILC classification, encompassing NK cells, ILC1s, ILC2s, ILC3s and LTi cells.252,253 NK cells detect “dysregulated self” through the integration of inhibitory inputs mediated by MHC class I-specific receptors and activating signals delivered by receptors such as natural killer group 2 member D. This balance-of-signals framework explains tolerance to healthy cells and killing of stressed or transformed targets.254 Activated NK cells eliminate infected cells through multiple cytotoxic modules.255 Granule exocytosis delivers perforin and granzymes to trigger apoptosis. TRAIL engages DR4/DR5, and FasL binds Fas to activate extrinsic apoptosis independently of MHC-I, ensuring redundant and flexible killing strategies. Although NK cells and ILC1s share several functional features, including IFN-γ production and T-bet dependence, they are not interchangeable populations. NK cells are strongly cytotoxic and express high levels of perforin, whereas ILC1s are typically noncytotoxic or only weakly cytotoxic and instead function as rapid responders at barrier and tissue sites. ILC1s contribute to early protection against viral infection and certain intracellular pathogens, including Toxoplasma gondii and Clostridioides difficile.256,257 In contrast, ILC2s are best known for mediating anti-helminth immunity, for example, during Nippostrongylus brasiliensis infection, and for facilitating tissue repair after injury resolution through factors such as AREG.253 Consistent with their potent type 2 effector capacity, dysregulated ILC2 activation is implicated in allergic pathologies, including asthma and atopic dermatitis.258 ILC3s are enriched at mucosal interfaces and play central roles in defense against extracellular bacteria as well as in the preservation of symbiosis with commensal microbiota.259 Their hallmark homeostatic effector cytokine, IL-22, promotes epithelial barrier integrity, supports intestinal homeostasis and enhances intestinal stem cell proliferation.260 LTi cells, while also RORγt dependent, are functionally specialized for embryonic lymphoid organogenesis and are indispensable for the formation of lymph nodes and Peyer’s patches through lymphotoxin-dependent mechanisms.261 Taken together, ILCs represent a highly heterogeneous and plastic arm of innate immunity. Several subsets exhibit tissue-resident features, and a more complete understanding of their ontogeny, phenotypic diversification, functional specialization and intersubset plasticity remains an important objective in the field. DCs DCs are a diverse lineage of hematopoietic-derived leukocytes that arise from common dendritic cell progenitors in the bone marrow and give rise to distinct subsets, such as conventional DCs.262 The hallmark function of DCs lies in their antigen-presenting capacity. Immature DCs continuously sample their environment through endocytosis, phagocytosis, and receptor-mediated uptake, internalizing both PAMPs and DAMPs.263 Upon activation, DCs upregulate MHC class I and II molecules, costimulatory receptors, and cytokines, allowing them to prime naive CD8 + T cells via cross-presentation and CD4 + T cells through classical MHC-II presentation.262 This dual pathway ensures robust cytotoxic T lymphocyte induction against intracellular pathogens and tumors while simultaneously instructing helper T-cell differentiation and humoral immunity. DCs are thus pivotal connectors between innate and adaptive immunity. They reside at mucosal and barrier interfaces, sense environmental cues via PRRs, and upon activation migrate to lymphoid tissues to initiate and shape T- and B-cell responses.264 Through their dual role as innate sentinels and antigen-presenting orchestrators, DCs not only mediate immediate host defense but also guide the formation of immunological memory, underscoring their indispensable function in immune regulation. Nonprofessional immune cells Nonprofessional immune cells, including epithelial cells and fibroblasts, act as critical sentinels of innate immunity despite not belonging to the hematopoietic lineage. Epithelial cells lining mucosal and barrier surfaces constitute the first physical and chemical shield against invading pathogens. They express PRRs such as TLRs and NLRs, enabling them to detect PAMPs and DAMPs.265 Upon activation, epithelial cells secrete antimicrobial peptides and cytokines, which orchestrate the recruitment and activation of innate lymphoid cells, DCs, and neutrophils.265 Notably, IFNs are among the most critical epithelial cytokines that maintain mucosal immunity. Two IFN families dominate epithelial antiviral defense, namely, type I IFNs (IFN-α/β) and type III IFNs (IFN-λs). Both converge on JAK-STAT signaling to induce antiviral ISGs, yet their tissue distribution and immunological footprint differ.266 Type I IFNs provide strong antiviral efficacy but can trigger broad inflammatory amplification due to ubiquitous IFNAR expression. In the epithelium, IFN-α/β enhance intrinsic restriction, promote antigen presentation, and potentiate chemokine-mediated recruitment of cytotoxic effectors.266 Type III IFNs are preferentially positioned for mucosal defense because IFNLR expression is enriched in epithelial compartments.267 IFN-λ can deliver high local antiviral activity with a comparatively reduced systemic inflammatory signature, making it an attractive framework for barrier-restricted immunomodulation.267 While both IFN families activate overlapping ISG sets, type I IFNs typically behave as a systemic amplifier, whereas type III IFNs function as a spatially confined mucosal shield.266,268 Collectively, epithelial IFNs couple epithelial defense with mucosal immune calibration, enabling pathogen clearance while limiting collateral barrier damage. Fibroblasts, beyond their structural role, actively participate in innate immunity by producing antimicrobial peptides such as cathelicidins that directly restrict pathogen growth.269 They secrete cytokines and chemokines, including IL-6 and CXCL8, which recruit and organize leukocytes within tissues, thereby amplifying early immune responses.270 However, fibroblasts can also exert immunosuppressive and regulatory functions. Lung fibroblast-derived PGE₂ promotes interleukin-10 (IL-10) production, whereas intestinal fibroblast-derived PGE₂ restrains the development of inflammatory macrophages to limit excessive inflammation.270 Physiological variation in innate immunity The homeostatic roles of innate immunity rely on a coordinated first-line barrier system and a second-line network of soluble mediators and innate effector cells. However, even under steady-state conditions, innate immune functional capacity is intrinsically heterogeneous, with substantial variability in baseline inflammatory tone and effector deployment. Sex differences, age-related changes, and circadian regulation are major physiological determinants of this functional heterogeneity. Accordingly, the following section summarizes how these factors dynamically shape innate immune homeostasis and responsiveness. Sex-dependent differences Innate immunity exhibits robust sexual dimorphism at the system level. Across many contexts, females tend to exhibit stronger nucleic acid sensing and type I IFN programs coupled with heightened inflammatory amplification, which may enhance early antimicrobial control but also increase susceptibility to immune-mediated pathology. Mechanistically, these differences reflect the integrated effects of sex chromosomes and sex hormone signaling on immune cells and cytokine networks. A major biological substrate for sex differences is the unequal genetic and epigenetic architecture of the X and Y chromosomes. The X chromosome is about three times larger than the Y chromosome in humans and encodes approximately 800 more protein-coding genes.271 The X chromosome encodes about 50 genes implicated in immune function, exemplified by signaling nodes (TLR7, IRAK1, NEMO, TASL, IL9R), a migration receptor (CXCR3), and factors controlling immune-cell differentiation and expansion (IL2RG, BTK).271 To balance X-linked gene dosage between XX and XY individuals, one X chromosome is largely transcriptionally silenced in XX cells through X-chromosome inactivation.272 However, an estimated 15–23% of X-linked genes in humans escape X-chromosome inactivation, and this escape is often cell-type specific, thereby creating sex-biased dosage and expression levels of innate immune genes.273,274 A prototypical example is TLR7, an X-linked pattern-recognition receptor for single-stranded RNA. Multiple studies have demonstrated that TLR7 can escape XCI in human immune cells, enabling biallelic expression in immune cells, lowering activation thresholds and increasing IFN-I amplitude upon nucleic acid stimulation.275,276 Beyond chromosomal effects, endocrine differences contribute substantially to sex-biased transcriptional landscapes in innate immunity. The principal gonadal steroid hormones include estrogens, progestogens, and androgens, while the corresponding receptors (ERα/ERβ, PR, and AR) are ligand-dependent transcriptional regulators.277 Transcriptomic profiling of human immune cells reveals approximately 1,875 transcripts with sex-biased expression, and this pattern is likely shaped by sex-dependent differences in gonadal steroid hormone levels.271,277,278 Estrogen signaling is characteristically biphasic and highly context-dependent.279 Low estrogens can enhance antiviral preparedness by elevating endosomal nucleic acid-sensing pathways and strengthening type I IFN output.271 In contrast, high estrogens can suppress inflammatory gain by attenuating NF-κB activity and limiting classical inflammatory polarization in macrophages.278 Progesterone generally acts as an immunoregulatory steroid with anti-inflammatory and proresolving effects across innate effector lineages. Progesterone-treated macrophages and DCs exhibit reduced activation and decreased secretion of IL-1β and TNF.280 Androgens broadly restrain inflammatory signaling.281 Androgen signaling can blunt PRR-driven transduction and downregulate key inflammatory nodes, including NF-κB and TLR4-associated transcriptional programs. Functionally, androgens reduce monocyte/macrophage production of TNF, IL-1β and IL-6.277 Differences in sex chromosomes and gonadal steroid hormone levels shape innate immune cell profiles, yielding distinct innate immune phenotypes across the sexes. Neutrophil counts are modestly yet significantly higher in females, and estrogen appears to enhance neutrophil effector function, particularly by promoting recruitment to inflamed tissues.282 In contrast, nonclassical monocytes are approximately threefold more abundant in the blood of adult males than females.283 Sex differences may also manifest as discordance between NK cell number and function. Males can show higher NK cell frequencies but reduced per-cell antiviral activity in some settings, potentially reflecting sex-biased expression of X-linked epigenetic regulators that shape cytotoxic programs.284 Sex-biased innate programming translates into measurable divergence in infection risk, disease severity, and vaccination outcomes. At the population level, males often show higher incidence or worse outcomes for multiple infectious syndromes.271 An explanation is that female-biased innate responsiveness can improve early pathogen restriction, especially IFN-I competence and rapid inflammatory amplification. However, the same heightened responsiveness may increase the likelihood of collateral tissue injury, particularly in organs where inflammation is tightly coupled to barrier disruption.271 Age-dependent changes Across the life course, innate immunity undergoes a staged transition from developmental immaturity to functional maturity and, ultimately, to age-associated decline. Fetal and neonatal innate immune responses are characteristically tuned to the unique physiologic constraints of early life, displaying reduced inflammatory gain and distinct effector thresholds. In later decades, however, the same system is progressively reshaped by aging, with emergent immunosenescence and chronic low-grade inflammation that collectively erode antimicrobial competence and increase the propensity for dysregulated inflammatory amplification. Thus, age constitutes a dominant physiological axis that redefines innate immune set points and reshapes health-disease trajectories. Compared with adults, neonates display attenuated innate immune competence. Neutrophils are limited both quantitatively and qualitatively.285 Neutrophils show a constrained reserve capacity and functional deficits in recruitment and migration.286 Selected granule-associated antimicrobial proteins, such as lactoferrins, are reduced, contributing to diminished microbicidal efficiency in early life. Monocytes/macrophages exhibit an immature APC phenotype with reduced MHC class II expression, suggesting weaker antigen presentation.287 Moreover, PRR responsiveness is dampened. TLR4 expression and/or downstream signaling is reduced, leading to weaker LPS-triggered TNF production compared with adult monocytes.288 Neonatal pDCs express TLR7 and TLR9 at levels comparable to those in adults, yet their capacity to secrete IFN-α/β upon viral challenge is markedly impaired.289 This functional deficit likely contributes to attenuated innate immunity to viruses such as RSV, HSV, and CMV in early life. Neonatal NK cells display reduced responsiveness to IL-2 and IL-15, with limited IFN-γ production, yet their activation threshold is relatively low, which may confer partial antiviral protection.290 With respect to complements, most complement components are present at markedly lower concentrations in neonatal serum with reduced biological activity.291 With advancing age, the innate immune architecture shifts again. Neutrophils in older adults have been reported as either largely stable or modestly increased.292 Aged neutrophils exhibit defects in migration and activation. A study revealed age-dependent rewiring of neutrophil function, with altered phagocytic capacity and NETotic potential.293 These defects cause neutrophil accumulation in the lung and accelerate vascular leakage, linking neutrophil dysfunction to remote organ injury in older hosts.294 Classical monocytes often remain relatively stable with age, whereas intermediate and nonclassical monocytes tend to expand.295 Chronic exposure to PAMPs and DAMPs sustains macrophage activation and fuels aging.296 Aged macrophages exhibit reduced phagocytosis and impaired MerTK-dependent efferocytosis, leading to apoptotic debris accumulation.297 Elevated ROS further promotes ADAM17-mediated MerTK shedding, reinforcing defective clearance and tissue inflammation.298 Aging has a limited impact on overall cDC abundance in many studies, yet pDCs tend to decrease with age.292 Notably, following influenza infection, older individuals exhibit reduced frequencies of IFN-α-producing pDCs compared with younger adults, consistent with an age-associated attenuation of the type I IFN axis.299 NK cell counts in older adults have been reported to either rise or remain stable.300 Importantly, kinetic studies provide mechanistic insight, showing preserved totals but approximately 50% lower generation rates in older individuals, suggesting compensatory persistence of long-lived NK populations.301 Cytotoxicity is frequently similar between young and old individuals, although both enhanced and reduced killing have been observed in smaller or context-specific studies.292 Circadian regulation The daily rotation of the Earth generates a highly conserved 24-h environmental cycle, driving the evolution of circadian rhythms across nearly all living organisms. In mammals, circadian clocks exert pervasive control over physiological processes, including innate immune responses. The innate immune system exhibits pronounced daily oscillations in its activity, orchestrated by the circadian clock machinery. Circadian rhythmicity is fundamentally generated by an intrinsic oscillatory network centered on a transcription-translation feedback loop. The core circuit is driven by the transcriptional activators CLOCK and BMAL1 and counterbalanced by the repressors PER and CRY.302 Mechanistically, the BMAL1-CLOCK heterodimer binds to E-box motifs in target gene promoters and drives rhythmic transcription, including that of PER and CRY. Following their synthesis, PER and CRY proteins progressively accumulate, enter the nucleus, and assemble into repressive complexes that inhibit BMAL1-CLOCK-mediated transcription. This repression attenuates the expression of BMAL1-CLOCK target genes and closes the negative feedback loop, thereby producing approximately 24-h oscillations. In addition to this central loop, other regulatory pathways, such as the ROR/REV-ERB and D-box modules, provide auxiliary layers of control that enhance the robustness, phase stability, and amplitude precision of the circadian system.302 The diurnal regulation of neutrophil biology emerges from the integration of cell-intrinsic circadian clocks and niche-derived signals. Neutrophils undergo rapid phenotypic and functional oscillations over their short lifespan.303 Mechanistically, BMAL1 drives CXCL2 expression, thereby coupling the molecular clock to CXCR2-dependent transcriptional and migratory programs in neutrophils.304 In the bone marrow niche, β3-adrenergic signaling in mesenchymal cells suppresses CXCL12 production during the daytime, whereas parasympathetic cholinergic inputs dampen sympathetic tone at night.305 Together, these coordinated neural and stromal signals establish a regulatory circuit that dynamically regulates neutrophil trafficking in the bone marrow niche. In macrophages, REV-ERB nuclear receptors function as central regulators at the intersection of circadian and immune pathways.306 REV-ERBα and REV-ERBβ repress transcription by targeting lineage-determining distal enhancers established by macrophage lineage-specifying factors, thereby limiting the expression of genes such as Mmp9 and Cx3cr1.307 In parallel, REV-ERBα directly binds to REV-ERB response elements within the Ccl2 promoter, thereby controlling macrophage inflammatory programs, including adhesion, migration, and integrin activation.308 In NK cells, PER1 functions as an essential regulator linking the circadian clock to effector activity. In the absence of PER1, NK cells retain circadian rhythmicity, but they exhibit altered rhythmic expression of key effector molecules, including IFN-γ, perforin, and granzyme B.306 Collectively, these findings establish the circadian clock as a fundamental layer of innate immune regulation that shapes the trafficking, activation, and effector functions of multiple innate immune cell populations. Innate immunity as a primary pathogenic effector Given its central role in maintaining physiological integrity, innate immunity becomes intrinsically pathogenic when its key proteins, pathways, or cellular effectors are disrupted. Below, we briefly survey classical disorders caused directly or predominantly by abnormalities in innate immune signaling molecules, effector proteins, or innate immune cells and organize them into immune hyperresponsiveness and immune deficiency. Through this framework, we highlight how disruption of innate immune programs can directly precipitate disease either by unleashing excessive inflammation or by compromising protective immunity (Table 4). Table 4Summary of innate immunity as a primary pathogenic effectorComponentAberrationAssociated DiseasesPathogenic MechanismInnate immune hyperactivationTLR7 mutationY264HSystemic lupus erythematosusLower activation threshold and sustained activation of cytokines and immune cellsNOD2 mutationsR702W, G908R and the L1007fsCrohn’s diseaseReduced antimicrobial peptides and lifting brakes on inflammationSTING mutationsV147L, N154S, V155M and F269SSTING-associated vasculopathy with onset in infancyConstitutive activation of STING pathway and excessive vasculopathy and endothelial inflammationNLRP3 mutationsA352V, V198M and R260WCryopyrin-associated periodic syndromesUncontrolled inflammasome activation and excessive IL-1β secretionMEFV (pyrin) mutationsV726A, M694V, M694I and M680IFamilial Mediterranean feverUncontrolled inflammasome activation and excessive IL-1β secretionC3 dysregulationPersistent activation by C3 mutations or regulatory abnormalitiesC3 glomerulopathySustained C3 activation accompanied by glomerular depositionNeutrophil hyperactivationNeutrophil hyperactivation by malignancies, G-CSF therapy, autoinflammatory and so onSweet syndromeSustained neutrophil activation and cutaneous-mucosal infiltrationInnate immune deficiencyCARD9 deficiencyDeficiencyPredisposition to fungiImpaired antifungal signaling causing susceptibility to fungal infectionsTRAF3 deficiencyDeficiencyPredisposition to Herpes simplex virus type 1Disrupted TLR3-mediated cell-intrinsic antiviral defenseIRAK4 deficiencyDeficiencyPredisposition to infectionsDisrupted MyD88-dependent signaling downstream of most TLRs and IL-1RIRF7 deficiencyDeficiencyPredisposition to influenzaAttenuated type I/III IFN signaling in pulmonary epithelial cells and pDCs enhances viral replicationLoss of function of the NADPH oxidase genesDeficiencyChronic granulomatous diseaseDeficiency of ROS pathways results in impaired microbial killing and clearanceC3 deficiencyDeficiencyRecurrent pyogenic infectionsDefects in the complement system causing increased vulnerability to diverse microorganismsNeutropeniaCongenital and acquired factors impairing neutrophil production, survival or traffickingNeutropeniaDeficiency of neutrophils causing heightened vulnerability to infectious diseases Summary of innate immunity as a primary pathogenic effector Innate immune hyperactivation Aberrations in the fundamental pathways, effector proteins, or cellular subsets of the innate immune system can profoundly disrupt immune homeostasis. Such dysregulation often results in excessive activation of signaling cascades, uncontrolled cytokine release, and sustained recruitment of inflammatory cells, thereby driving hyperinflammatory disease states. TLR7 mutation TLR7 dysregulation can induce lupus-like disease in mice and has been identified as a pivotal pathogenic effector contributing to human systemic lupus erythematosus (SLE).309,310 The Y264H mutation in TLR7 lowers the activation threshold and allows direct sensing of guanosine and cGMP beyond canonical GU-rich RNA.310 This mutation drives sustained activation of B cells, while pDCs are likewise implicated as critical effectors in disease pathogenesis. Endogenous RNA‒protein autoantigens trigger TLR7 in pDCs to secrete IFN-α, which further upregulates TLR7 trafficking and creates a self-reinforcing IFN loop linked to disease activity.311 NOD2 mutations Mutations in NOD2, most notably R702W, G908R, and the L1007fs, confer a strong and reproducible genetic risk for Crohn’s disease, particularly affecting the ileum.312,313 NOD2 is a cytosolic PRR for microbial muramyl dipeptide that signals via NF-κB/MAPK, inducing antimicrobial and regulatory programs. NOD2 is highly expressed in ileal Paneth cells.314 Multiple studies link NOD2 dysfunction to reduced Paneth cell antimicrobial peptide output and reduced mucosal defense.315 Beyond loss of mucosal defense, NOD2 normally restrains excessive TLR signaling via IRF4-dependent negative regulation.316 Thus, NOD2 dysfunction can simultaneously impair bacterial clearance and lift brakes on inflammation, amplifying mucosal injury. STING mutations STING-associated vasculopathy with onset in infancy is driven by pathogenic mutations in TMEM173, most commonly observed in variants including V147L, N154S, V155M, and F269S.317–319 Mutations in TMEM173 destabilize the autoinhibited state, driving constitutive TBK1-IRF3 activation and type I/III IFN outputs without cGAMP.317 Both patient-derived and experimental models indicate that STING activation within endothelial cells initiates proinflammatory transcriptional cascades, endothelial damage, and cytokine-driven toxicity, ultimately leading to acral ischemia and systemic vasculitis.318 Persistent STING activation in pulmonary compartments drives type-I IFN-dominated alveolitis, chemokine production, and progressive fibro-inflammatory interstitial lung disease.317 More broadly, SAVI belongs to the expanding group of interferonopathies, a set of inherited inflammatory disorders unified by chronic and inappropriate activation of IFN signaling.320 They are mainly caused by self-nucleic acid accumulation, sensor or adaptor hyperactivation, or deficiency of molecules that negatively regulate interferon production and signaling. Mechanistically, these defects sustain JAK-STAT signaling and amplify interferon-stimulated gene programs, thereby perpetuating sterile inflammation and tissue damage. Clinically, interferonopathies commonly manifest with recurrent fever, skin lesions, interstitial lung disease, and variable autoimmune features.321 NLRP3 mutations NLRP3 mutations result in aberrant priming or spontaneous activation of the inflammasome.322 This drives excessive production of IL-1β and IL-18 and induces GSDMD-mediated pyroptosis under minimal stimulation, ultimately causing cryopyrin-associated periodic syndromes (CAPS).323–325 NLRP3 mutations associated with CAPS include well-characterized variants such as A352V, V198M, and R260W.326,327 In patients with CAPS, inflammasome hyperactivation in the skin and joints gives rise to urticarial-like but nonpruritic rashes, arthralgia or frank arthritis, and episodes triggered by cold exposure.328 Continuous cytokine signaling drives severe complications such as sensorineural hearing loss and aseptic meningitis.328 Long-standing systemic inflammation predisposes patients with CAPS to AA amyloidosis, which frequently involves the kidneys and may progress to chronic kidney disease.329 MEFV (pyrin) mutations Familial Mediterranean fever (FMF) is a prototypic monogenic autoinflammatory disease caused by mutations in the MEFV gene, which encodes the inflammasome regulator pyrin.330 Pathogenic MEFV variants impair pyrin-mediated control of caspase-1 activation, leading to uncontrolled IL-1β release and recurrent inflammatory flares. Most cases of FMF are attributable to four recurrent founder mutations in MEFV, including V726A, M694V, M694I and M680I.331 FMF is characterized by recurrent self-limiting febrile episodes accompanied by serosal inflammation, most commonly manifesting as peritonitis, pleuritis, or arthritis. Additional clinical features include erysipelas-like erythema, myalgia, and in severe or untreated cases, the development of secondary amyloidosis leading to renal dysfunction.332 C3 dysregulation C3 dysregulation drives the development of C3 glomerulopathy, which is defined pathologically by predominant C3 deposition within glomeruli and represents a paradigm of complement-mediated kidney injury.333 In C3G, aberrant alternative pathway activation on glomerular endothelium and mesangium drives deposition of C3 fragments, subendothelial expansion, mesangial proliferation, and ultimately a membranoproliferative-glomerulonephritis-like pattern, while C5a signaling recruits leukocytes and amplifies inflammation.334 In parallel, podocytes and the glomerular basement membrane accumulate intramembranous C3 deposits that disrupt GBM architecture and slit diaphragms, leading to proteinuria, progressive scarring, and a substantial risk of chronic kidney disease or end-stage kidney disease over time.335 Clinically, C3G presents across ages with hematuria, subnephrotic to proteinuria, hypertension, and progressive renal impairment.336,337 Neutrophil hyperactivation Neutrophil hyperactivation is the proximate and disease-defining driver of Sweet syndrome, with malignancies, G-CSF therapy, and autoinflammatory states recognized as common triggers.338 Pathogenesis reflects cytokine-driven autoinflammation centered on myeloid activation, with IL-1-dependent signaling regarded as a key upstream driver.339 Lesional histology uniformly demonstrates dense, sterile dermal neutrophilic infiltrates with activation signatures and proinflammatory cytokines.338 Hyperactivated neutrophils infiltrate the skin, releasing proteases and ROS and forming NETs, thereby amplifying tissue injury and systemic inflammation.340 Clinically, Sweet syndrome is characterized by high fever, painful edematous plaques or nodules, neutrophilia, and rapid corticosteroid responsiveness.338 Innate immune deficiency Innate immunity is indispensable for early host defense, and disruption of its core molecular or cellular components can directly give rise to immunodeficiency disorders. Pioneering studies in children with rare mutations affecting innate immune pathways established a new conceptual framework in human immunology, demonstrating that monogenic defects in pattern-recognition receptors, adaptors, signaling intermediates, IFN circuits, complement components, or innate immune cells can cause highly selective yet often life-threatening susceptibility to infection. These disorders have collectively revealed that human innate immune deficiency is not merely a state of generalized immune weakness but rather a spectrum of pathway-specific diseases with distinct infectious, inflammatory, and tissue-restricted phenotypes. CARD9 deficiency Deficiency of CARD9, a central adaptor downstream of β-glucan-sensing CLRs, predisposes individuals to invasive fungal diseases, most notably deep dermatophytosis and central nervous system candidiasis.341,342 Upon SYK activation, the signaling pathway propagates NF-κB signaling and drives the production of antifungal cytokines, such as IL-1β, IL-6, and IL-23. Loss of CARD9 disrupts these circuits, resulting in impaired cytokine release and defective chemokine programs essential for antifungal immunity. Mechanistically, impaired CARD9 signaling attenuates IL-23-driven Th17 polarization and neutrophil-mobilizing chemokines, fostering susceptibility to invasive dermatophytosis and systemic fungal disease.341 In the CNS, CARD9-positive microglia orchestrate an IL-1β-CXCL1 axis critical for neutrophil recruitment. Its absence leads to defective neutrophil influx and uncontrolled intraparenchymal Candida proliferation.343,344 TRAF3 deficiency TRAF3 is best characterized in the TLR3/TLR4-TRIF and RLR-MAVS pathways, in which it promotes recruitment of TBK1/IKKε, phosphorylation of IRF3/IRF7, and induction of type I IFNs and ISGs.345 Classical TRAF3 deficiency disrupts TLR3-mediated cell-intrinsic antiviral defense by attenuating IFN-β, IFN-λ, and IL-6 production, thereby conferring selective predisposition to severe HSV-1 encephalitis rather than broad infectious susceptibility.346 Emerging data further suggest that heterozygous TRAF3 loss-of-function may extend this phenotype to recurrent bacterial infection and immune dysregulation.347 IRAK4 deficiency IRAK4 is a central serine/threonine kinase in innate immunity that serves as an essential signaling hub downstream of most TLRs and IL-1R family members.67 Recruited by MyD88 upon receptor activation, IRAK4 nucleates myddosome assembly and couples innate sensing to downstream inflammatory signal propagation.348 IRAK4 deficiency is a rare inborn error of immunity that classically causes profound impairment of TLR/IL-1R signaling and a selective predisposition to infections, particularly in infancy and early childhood. In mouse models, loss of IRAK4 confers broad vulnerability to a wide range of pathogens, including bacteria, viruses, parasites, and fungi, underscoring the central role of this axis in orchestrating innate host defense across multiple infectious contexts.349 Clinically, IRAK4 deficiency is defined by early-life susceptibility to invasive bacterial infection, with meningitis, sepsis, pneumonia and soft-tissue infection as major manifestations.350 A hallmark feature is attenuated inflammatory signaling despite severe infection, with the greatest risk occurring in childhood and declining with age.351 IRF7 deficiency Genetic studies have demonstrated that loss-of-function mutations in IRF7 abolish type I and III IFN amplification, predisposing affected individuals to life-threatening influenza infection.352 IRF7 is the master transcriptional amplifier of type I and type III IFN responses and is essential for sustaining IFN production following viral sensing through RIG-I, TLR7/8, and TLR3. IRF7 deficiency impairs the antiviral IFN-producing capacity of plasmacytoid DCs and reduces type I IFN expression in alveolar epithelial cells, thereby enhancing influenza virus replication and predisposing individuals to severe and life-threatening influenza.352–354 Loss of function of the NADPH oxidase genes Mutations in genes encoding NADPH oxidase subunits underlie chronic granulomatous disease (CGD), a prototypical inherited disorder of the innate immune system characterized by defective phagocyte respiratory burst.355 The disease arises from germline mutations in subunits of the NADPH oxidase complex, particularly CYBB and NCF1, which disrupt the generation of superoxide and downstream ROS.356 In the absence of functional NADPH oxidase, neutrophils and monocytes fail to mount an oxidative burst, permitting unchecked survival of catalase-positive bacteria and fungi and driving granulomatous inflammation.357 Clinically, CGD manifests with recurrent pneumonia, cutaneous, hepatic, and lymph node abscesses, invasive aspergillosis, and chronic inflammatory complications, including colitis.358 C3 deficiency C3 sits at the central convergence point of the classical, lectin, and alternative pathways, orchestrating multiple complement effector functions. Individuals with C3 deficiency exhibit profound innate immune defects and are highly susceptible to recurrent pyogenic infections.359 Without C3b/iC3b deposition, macrophage and neutrophil uptake via complement receptors is severely diminished, weakening opsonization and clearance of pathogens. Loss of C3a generation further impairs neutrophil chemotaxis, mast cell degranulation, and vascular responses, dampening early inflammatory activation. In parallel, the absence of C3 abrogates C5 convertase activity, eliminating C5a-mediated amplification and MAC formation. Clinically, these defects translate into recurrent and invasive infections, particularly with Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae.360–362 Neutropenia Neutropenia is classically defined by an absolute neutrophil count <1.5 × 109/L and encompasses acquired and congenital disorders ranging from benign variants to life-threatening immunodeficiency.363 Pathogenetically, neutropenia arises from impaired granulopoiesis, immune-mediated peripheral destruction, or aberrant margination.364 At a molecular level, ELANE mutations drive misfolding of neutrophil elastase, activation of the unfolded-protein response, and apoptosis of promyelocytes, providing a direct mechanism for congenital neutropenia.365 Likewise, HAX1 mutations precipitate mitochondrial apoptosis in myeloid precursors, causing autosomal-recessive severe congenital neutropenia.366 Consequently, neutropenic patients are predisposed to mucocutaneous, skin, and bloodstream infections caused by pathogens.367 The depth and duration of neutropenia determine infection risk, and seminal work showed steep increases in invasive bacterial infections once the absolute neutrophil count falls below 0.5 × 109/L and with prolonged neutropenia.368 Clinically, patients with neutropenia present with persistent fever, mucosal inflammation, and life-threatening infections.369 Innate immunity as a participant in disease pathogenesis Beyond its role in disease initiation, innate immunity profoundly influences disease progression through dynamic and multilayered mechanisms. We therefore analyze its pathogenic involvement along three axes defense, homeostasis, and surveillance and select representative disorders where failure in each axis leads to characteristic pathological manifestations (Fig. 6). This approach underscores how the delicate balance of innate immune activity determines the transition from protective immunity to disease. Representative pathological modes of innate immunity in disease development. a Excessive innate immune activation in innate immune defense. Using ARDS as an example, innate immune cells recognize PAMPs and DAMPs and initiate signaling cascades that amplify cytokine networks, leading to sustained immune cell recruitment and activation. This hyperactivation drives vascular dilation and tissue injury, which in turn exposes additional DAMPs. Barrier disruption further facilitates pathogen invasion and exposure to PAMPs, thereby forming a self-perpetuating cycle of innate immune overactivation. b Innate immune suppression in innate immune surveillance. Under physiological conditions (black arrows), NK cells recognize, activate, and ultimately eliminate tumor cells. In pathological contexts (red arrows), tumors exploit multiple mechanisms of immune evasion. Recognition escape occurs through extracellular factors and physical barriers established by nonmalignant stromal cells. Immune checkpoints and suppressive cell populations, such as myeloid-derived suppressor cells, impair NK cell activation. Moreover, tumor-derived signals drive immunosuppressive polarization, for instance, monocyte reprogramming toward an M2-like phenotype, fostering a suppressive tumor microenvironment. c Defective clearance in innate immune homeostasis. Using a chronic model of atherosclerosis as an example, lipoprotein deposition in the vessel wall is normally recognized by monocytes, which initiate transcriptional programs enabling phagocytosis and clearance. In chronic disease, persistent lipoprotein accumulation drives continuous activation and phagocytic engagement of innate cells. Once the metabolic threshold of immune cells is exceeded, they undergo pathological transformation, leading to necrosis and lipid accumulation. These necrotic cores release additional danger signals, thereby exacerbating the cycle of impaired clearance and chronic inflammation. This figure was created with BioRender (http://biorender.com/) Dysregulated immune defense in ARDS and hyperinflammatory tissue injury The preceding section discussed the protective role of innate immunity in infection control. In disease states, however, innate immunity can become excessively activated, engaging in a triangular cycle of recognition, amplification, and tissue injury. This overdrive converts a defense mechanism into a pathogenic effector. Acute respiratory distress syndrome (ARDS) represents a prototypical example of this effect, where dysregulated innate immunity drives lung injury and contributes directly to disease progression. The initiation of ARDS involves exaggerated innate immune activation triggered by infectious or sterile insults such as trauma or aspiration.370 PAMPs and DAMPs are recognized by PRRs on AMs and epithelial cells, leading to activation of the NF-κB and IRF pathways.371,372 These transcriptional programs induce high levels of TNF-α, IL-1β, IL-6, CXCL8, and lipid mediators.373 In parallel, engagement of the NLRP3 inflammasome leads to caspase-1 activation and the release of IL-1β and IL-18.374 Complement activation further amplifies this cascade, with C5a-C5aR1 signaling driving neutrophil chemotaxis, endothelial permeability, and coagulopathy.375 Proinflammatory mediators, complement activation, and increased vascular permeability synergistically orchestrate the recruitment of neutrophils and monocytes to sites of inflammation. Cascaded activation through PRR signaling networks, together with complement-mediated amplification and cytokine-cellular feedback loops, orchestrates escalating innate immune responses at sites of tissue injury and infection. The very effectors that normally provide antimicrobial defense cause collateral tissue destruction in ARDS. Recruited neutrophils release myeloperoxidase, elastase, MMPs, and ROS, which degrade the extracellular matrix (ECM) and disrupt the alveolar-capillary barrier.373 NETs, although antimicrobial, injure epithelial and endothelial layers and activate inflammasomes.376 Damage to type I and Ⅱ alveolar epithelial cells results in barrier denudation, hyaline membrane formation, surfactant inactivation, and impaired alveolar fluid clearance.370 Endothelial cells, connected by tight junctions and adherens junctions, undergo junctional disruption and glycocalyx shedding, promoting vascular leakage and microthrombosis.370 These processes culminate in diffuse alveolar damage and impaired gas exchange, the defining pathological features of ARDS. Excessive innate immune activation compromises tissue integrity and promotes the release or exposure of DAMPs, which are endogenous injury-associated molecules derived from damaged alveolar epithelial cells, endothelial cells, and infiltrating leukocytes. Here, DAMPs are considered specifically in the context of ARDS-associated lung injury rather than as a broad category encompassing all forms of sterile inflammation. Representative pulmonary DAMPs include mitochondrial DNA, extracellular histones, and extracellular matrix fragments. By engaging cognate PRRs, these molecules sustain a feedforward inflammatory circuit that aggravates alveolar-capillary barrier disruption, impairs local clearance mechanisms and may create conditions conducive to secondary microbial colonization and invasion. This DAMP-driven amplification paradigm is particularly evident in infectious and autoimmune diseases, in which persistent tissue injury and immune activation perpetuate DAMP release and PRR signaling. The resolution of ARDS requires the orchestrated clearance of infiltrating leukocytes and proinflammatory mediators, the active removal of alveolar edema fluid, and the repair of disrupted alveolar-capillary structures to reestablish gas exchange.373 Inflammatory neutrophils undergo apoptosis, after which they are engulfed by AMs through efferocytosis, preventing secondary necrosis and the release of DAMPs.377 Repair following inflammation drives macrophage reprogramming from a proinflammatory M1-like state toward a proresolving M2-like phenotype, leading to enhanced secretion of IL-10 and TGF-β that promote epithelial repair.378 The balance of chemokines and cytokines shifts from proinflammatory to anti-inflammatory, characterized by IL-10 and TGF-β limiting immune injury and factors such as epidermal growth factor and granulocyte-macrophage colony-stimulating factor stimulating alveolar type II cell proliferation and conversion to type I cells to restore epithelial barrier integrity.370,379 The lipid mediator profile shifts toward proresolving mediators, including resolvins, which may terminate neutrophil recruitment, enhance macrophage efferocytosis, and stimulate epithelial and endothelial restitution.373,380 Resolvins are among the most prominent specialized proresolving mediators. They are grouped into E-series and D-series, mainly biosynthesized from ω-3 polyunsaturated fatty acids.381,382 Resolvins restrain excessive recruitment and transendothelial migration and dampen collateral effector outputs, thereby curtailing bystander damage that fuels barrier breakdown.383 Simultaneously, resolvins promote a resolution-competent state by enhancing efferocytosis of apoptotic PMNs and cellular debris and by limiting feed-forward production of pro-inflammatory cytokines.383 In ARDS, impaired biosynthesis, accelerated degradation, or limited ω-3 substrate supply lead to dysregulation of resolvin, thereby sustaining neutrophil-dominant inflammation, inefficient macrophage efferocytosis, and persistent endothelial hyperpermeability, ultimately prolonging pulmonary edema and hypoxemia.384,385 Collectively, ARDS is used here as a prototypical example to illustrate the sequential process by which innate immunity contributes to disease pathogenesis through recognition, amplification and injury. Similar patterns of immune overactivation that drive disease progression are evident in many disorders, particularly in acute inflammatory diseases. In the early phase, the innate immune system recognizes PAMPs or DAMPs via PRRs, initiating immune activation. This is followed by a cascade of signaling pathways, cytokine and complement release, and immune cell recruitment that amplifies local inflammation. Ultimately, the exaggerated innate response causes collateral tissue injury, exposing new DAMPs or disrupting epithelial and endothelial barriers, thereby facilitating microbial invasion and secondary insults. This creates a vicious cycle in which each round of recognition fuels further immune activation. Understanding how the host terminates this self-perpetuating innate immune loop to prevent excessive tissue damage represents a critical frontier in the study of disease mechanisms. Immune surveillance failure in the tumor microenvironment Immune surveillance constitutes the third core function of the immune system, complementing host defense and immune homeostasis. It refers to the continuous monitoring of tissues to detect and eliminate aberrant or transformed cells before they evolve into malignant tumors. While adaptive immunity provides antigen-specific recognition, innate immunity represents the frontline of this process, employing germline-encoded receptors to sense cellular stress, DNA damage, and metabolic dysregulation. NK cells, DCs, macrophages, and innate lymphoid cells orchestrate cytotoxic and regulatory pathways that act as an early barrier against tumor initiation.253 Evasion of innate immune recognition In the steady state, innate immune cells detect transformed or stressed cells through the imbalance of activating and inhibitory signals. NK cells play a central role, recognizing tumor cells with reduced MHC-I expression or upregulated stress-induced ligands such as MICA/B and ULBPs.254 Upon recognition, NK cells release perforin and granzymes to induce apoptosis and engage death receptor pathways to eliminate malignant cells.386 DCs simultaneously capture tumor-derived antigens and present them to T cells, bridging innate and adaptive responses, while macrophages phagocytose dying tumor cells and secrete inflammatory mediators to amplify local antitumor immunity.387,388 Taken together, the entire process proceeds through innate immune cell recognition, activation, and ultimately effector-mediated cytotoxicity. Tumors generate dense ECM deposits composed of collagen, fibronectin, and proteoglycans, which physically obstruct immune infiltration.389 Cancer-associated fibroblasts actively remodel the ECM and increase matrix stiffness, creating high interstitial pressure that restricts NK cell and macrophage trafficking into tumor nests.389,390 Additionally, hypoxic niches within the tumor microenvironment (TME) impair the migration of cytotoxic innate cells and favor the recruitment of immunosuppressive myeloid populations.391 Beyond ECM barriers, malignant cells are embedded within diverse nontumor cell populations that disguise them from immune recognition. Stromal fibroblasts secrete chemokines such as CXCL12 that form protective gradients, physically excluding NK cells and DCs from tumor cores.392 Endothelial and vascular cells express adhesion molecules and inhibitory ligands that regulate leukocyte trafficking, further limiting the access of cytotoxic innate cells.393 Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) accumulate at invasive margins, forming an immune shield that suppresses effector cell entry and recognition of tumor cells.388,394 Innate immune cells as accomplices in the tumor microenvironment Tumors exploit multiple checkpoint pathways to subvert innate immune surveillance by directly suppressing macrophage and NK cell function. Engagement of the PD-1/PD-L1 axis on NK cells attenuates cytokine production and degranulation, while tumor upregulation of HLA-E restrains NK cell cytotoxicity through NKG2A signaling.395 Similarly, the TIGIT/CD155 pathways dampen NK cell activation and reduce IFN-γ secretion.396 In parallel, overexpression of the “don’t eat me” signal CD47 on tumor cells engages SIRPα on macrophages, thereby blocking phagocytosis even in the presence of opsonizing antibodies.397 Collectively, these inhibitory circuits establish a potent immune evasion network that cripples innate effector functions within the TME. The TME is enriched with soluble and metabolic inhibitors of innate immunity. Cytokines such as IL-10 and TGF-β skew macrophages toward immunosuppressive states, inhibit NK cell cytotoxicity, and reduce DC maturation.398 The accumulation of metabolic products such as lactate and kynurenine induces metabolic paralysis in NK and myeloid cells, suppressing glycolysis and oxidative phosphorylation and thereby impairing their effector capacity.399,400 TAMs originate both from circulating monocytes recruited by tumor-derived chemokines such as CCL2 and CSF-1 and from tissue-resident macrophages that are re-educated by tumor-derived signals.401 Within the hypoxic and nutrient-deprived TME, TAMs undergo profound metabolic reprogramming, including enhanced oxidative metabolism, increased arginase-1 activity, and lipid accumulation, which collectively drive polarization toward an M2-like phenotype characterized by the secretion of IL-10 and TGF-β.402 Functionally, these M2-like TAMs exert potent protumor effects by suppressing NK and T-cell activity, releasing VEGF and MMPs to stimulate angiogenesis and ECM remodeling, and producing growth factors that promote tumor cell proliferation and metastatic dissemination.403 MDSCs represent a heterogeneous population of immature myeloid cells that expand under the influence of tumor-derived factors such as GM-CSF.394 Within the TME, MDSCs exert potent protumor functions through multiple mechanisms.404 They suppress innate immunity by downregulating the activating receptor NKG2D on NK cells, thereby attenuating cytotoxicity.405 In addition, MDSCs secrete immunosuppressive cytokines such as IL-10 and TGF-β, further reinforcing a tolerogenic microenvironment.406 Beyond immune suppression, they contribute directly to tumor progression by releasing VEGF and matrix-remodeling enzymes, which promote angiogenesis, enhance ECM degradation, and facilitate metastatic dissemination.407 In summary, cancer exemplifies the diverse strategies by which diseases evade innate immune surveillance. By disrupting recognition, impairing activation pathways, and even reprogramming innate immune cells toward immunosuppressive phenotypes, malignant cells can circumvent innate detection and cytotoxic elimination, ultimately achieving immune escape. Homeostatic imbalance in atherosclerosis and failed efferocytosis Beyond host defense and immune surveillance, immune homeostasis represents a fundamental function of the innate immune system. It ensures the maintenance of tissue integrity by clearing apoptotic cells, misfolded proteins, metabolic byproducts, and extracellular debris through phagocytosis and efferocytosis. Innate immune cells coordinate with soluble mediators such as complement proteins and opsonins to maintain this equilibrium. Failure of these mechanisms disrupts tissue balance, giving rise to persistent inflammation, maladaptive repair, and chronic diseases. Disruption of homeostatic clearance In a healthy arterial wall, low-density lipoproteins that infiltrate the subendothelial space are recognized as altered self-structures and are subject to transient inflammation aimed at clearance. Innate immune activation recruits monocytes, which differentiate into macrophages, as well as neutrophils and DCs, orchestrated by cytokines and chemokines such as CCL2, IL-1β, and TNF-α.408 Activated macrophages phagocytose and metabolize modified lipids, while neutrophils and DCs amplify inflammatory signaling and antigen presentation.409 Once clearance has been achieved, beneficial factors such as IL-10 and TGF-β are released, presumably signaling that no additional inflammatory cells need to be recruited to the site of injury and thereby restoring vascular homeostasis.410 When lipid influx and accumulation exceed the clearance capacity, immune equilibrium fails, and chronic inflammation ensues. Macrophages internalize excessive oxidized LDL through scavenger receptors such as CD36 and SR-A, and the accumulation of cholesterol esters leads to foam cell transformation and metabolic stress.411 Defective phagocytosis and efferocytosis occur in macrophages within atherosclerotic plaques, and this impaired clearance capacity promotes plaque inflammation, foam cell accumulation, and increased plaque vulnerability.412,413 Vascular smooth muscle cells attempt to stabilize plaques by producing extracellular collagen and forming a fibrous cap. However, persistent inflammation weakens this compensatory process, rendering plaques unstable.414 Persistent oxidized LDL perpetuates chemokine gradients, driving continuous infiltration of monocytes and neutrophils. This influx amplifies cytokine release and further impairs local resolution mechanisms. Amplification through DAMP release and unresolved inflammation As macrophages and foam cells reach the limit of their metabolic and phagocytic capacity, they undergo apoptosis and necrosis. Necrotic cell death within the plaque contributes to the expansion of the necrotic core, releasing proteolytic enzymes, oxidized lipids, and DAMPs, which further stimulate PRRs such as TLRs and NLRs on surrounding cells.415,416 The release of intracellular contents and oxidized lipids perpetuates a cycle of innate immune activation. Each new wave of debris acts as a fresh inflammatory trigger, fueling macrophage recruitment and failed efferocytosis. This self-perpetuating inflammatory loop resembles a snowball effect, whereby unresolved debris accumulation and defective immune clearance sustain chronic vascular inflammation. Collectively, atherosclerosis illustrates how disruption of innate immune homeostasis initiates a self-perpetuating cycle of chronic inflammation. Foreign or modified self-antigens, such as oxidized lipids, initially trigger inflammation and are normally cleared by phagocytic cells. However, persistent exposure overwhelms phagocytes, leading to progressive decompensation characterized by diminished metabolic capacity and impaired phagocytosis and efferocytosis. Once the burden exceeds cellular thresholds, phagocytes undergo apoptosis or necrosis, releasing intracellular debris and oxidized lipids into the lesion. These danger signals act as fresh inflammatory stimuli, fueling a vicious cycle. Breaking this maladaptive loop offers a promising strategy to re-establish immune homeostasis and provides a conceptual framework for the treatment of chronic inflammatory diseases. Emerging therapeutic strategies targeting innate immunity Innate immunity exerts a pivotal influence on both health and disease and consequently represents a major focus for therapeutic development. A vast number of agents targeting key innate immune proteins and signaling pathways are under investigation, with thousands in preclinical pipelines and an increasing proportion advancing into clinical trials or reaching regulatory approval. This section focuses specifically on agents that have entered clinical evaluation or achieved market authorization and summarizes progress across four domains: critical signaling pathways, representative cytokines, the complement system, and innate immune cells (Table 5). Table 5Summary of therapeutic strategies targeting innate immunityCategoryMedicineTargetMechanismConditionClinical stageTLR agonistsRintatolimod (Ampligen)TLR3DsRNA analogs activating the TLR3-TRIF axisME/CFSApprovalTLR agonistsPoly-ICLC (Hiltonol)TLR3Synthetic dsRNA activating TLR3Vaccine adjuvants or immunotherapiesPhase Ⅰ(NCT02071095), phase Ⅱ(NCT02423863)TLR agonistsImiquimodTLR7Activation of TLR7Actinic keratosis, superficial basal cell carcinoma and cutaneous wartsApprovalTLR agonistsVesatolimodTLR7Activation of TLR7Chronic hepatitis BPhase Ⅱ (NCT02166047)TLR agonistsResiquimodTLR7/8Activation of TLR7/8MelanomaPhase Ⅰ (NCT00470379)TLR antagonistsHydroxychloroquineTLR7/9Alkalinization of endosomes and blockage of nucleic acid-TLR bindingSLEApprovalTLR antagonistsAfimetoranTLR7/8Inhibition of TLR7/8SLEPhase Ⅱ (NCT04895696)TLR antagonistsEnpatoranTLR7/8Inhibition of TLR7/8SLEPhase Ⅱ (NCT05162586)IRAK4 inhibitorsPF-06650833IRAK4Inhibition of IRAK4 kinase activityRAPhase Ⅱ (NCT02996500)IRAK4 inhibitorsKT-474IRAK4PROTAC-mediated degradation of IRAK4HS, ADPhase Ⅰ (NCT04772885)STING agonistsADU-S100STINGSynthetic cyclic dinucleotides activating STINGMalignancyPhase Ⅰ (NCT02675439), phase Ⅱ (NCT03937141)STING agonistsE7766STINGMacrocycle-bridged STING agonistMalignancyPhase Ⅰ(NCT04144140, NCT04109092)STING agonistsSNX281STINGNonnucleotide STING activatorsMalignancyPhase Ⅰ (NCT04609579)cGAS inhibitorsIMSB301cGASOral inhibition of cGASAutoimmune disordersPhase Ⅰ (ISRCTN90049550)cGAS inhibitorsVENT-03cGASOral inhibition of cGASLupus erythematosusPhase Ⅰ (CTIS 2023-507504-31-00)NLRP3 inhibitorsColchicineTubulin/ASCIndirect inhibition of NLRP3GoutApprovalNLRP3 inhibitorsDapansutrileNLRP3Selective inhibition of NLRP3Acute gout flarePhase Ⅱ (EudraCT 2016-000943-14)NLRP3 inhibitorsNT-0796NLRP3Brain-penetrant inhibition of NLRP3Cardiovascular DiseasesPhase Ⅰ (NCT06129409)NLRP3 inhibitorsZYIL1NLRP3Disrupts ASC oligomerizationALS, CAPSPhase Ⅱ (NCT05981040, NCT05186051)TNF-α inhibitorsInfliximabTNF-αChimeric mouse-human IgG1CD, UC and RAApprovalTNF-α inhibitorsAdalimumabTNF-αFully human IgG1CD, UC, psoriatic arthritis and ASApprovalTNF-α inhibitorsEtanerceptTNF and LTαCytokine decoysRA, JIA and ASApprovalIL-1 inhibitorsCanakinumabIL-1βFully human IgG1CAPS and JIAApprovalIL-1 inhibitorsRilonaceptIL-1α/βCytokine decoysCAPS and recurrent pericarditisApprovalIL-1 inhibitorsAnakinraIL-1R1Blocking IL-1R1RA, CAPS and goutApproval, Phase Ⅱ (NCT03002974, for gout)IL-6 inhibitorsSiltuximabIL-6Chimeric monoclonal antibodyMulticentric Castleman’s diseaseApprovalIL-6 inhibitorsTocilizumabIL-6RBlocking IL-6RRA, JIA, GCA and CRS following CAR-T therapyApprovalIL-6 inhibitorsSatralizumabIL-6RBlocking IL-6RNMOSDApprovalInterferon signaling modulatorRecombinant IFN-β-1a/1bIFNAR1/2Exogenous IFN supplementation for immunomodulationRelapsing-remitting multiple sclerosisApprovalInterferon signaling modulatorIFN-γ1bIFNGR1/IFNGR2Exogenous IFN supplementation for immunodeficiencyCGDApprovalInterferon signaling modulatorBaricitinibJAK1/JAK2Inhibition of interferon signalingRA and atopic dermatitisApprovalInterferon signaling modulatorRuxolitinibJAK1/JAK2Inhibition of interferon signalingMyelofibrosisApprovalInitiation of complementsANX005C1qHumanized antibody for C1qGuillain-Barré syndromePhase Ⅲ (NCT04701164)Initiation of complementsSutimlimabC1sHumanized antibody for C1sCold agglutinin diseaseApprovalInitiation of complementsBerinertC1r/C1s, MASP-1/2Exogenous C1-INH supplementationHereditary angioedemaApprovalBlockade of complement complexPegcetacoplanC3C3 inhibitorGeographic atrophy and PNHApprovalBlockade of complement complexEculizumabC5Humanized antibody for C5PNH, aHUS, gMG and NMOSDApprovalBlockade of complement complexRavulizumabC5Humanized antibody for C5PNH, aHUS, gMG and NMOSDApprovalAntagonists of terminal phaseAvacopanC5a receptorInhibition of the C5a-C5aR1 axisANCA-associated vasculitisApprovalAntagonists of terminal phaseVilobelimabC5aSelective neutralization of C5aCOVID-19Emergency Use AuthorizationTargeting neutrophilNavarixin (MK-7123)CXCR1/CXCR2CXCR1/2 antagonism, reducing neutrophil recruitment and tissue infiltrationCOPD, MalignancyPhase Ⅱ (NCT03473925, NCT01006616)Targeting neutrophilSivelestatNeutrophil elastaseInhibitor for neutrophil elastaseALI/ARDSApprovalTargeting monocyte/macrophagePexidartinibCSF1RInhibition of the CSF1/CSF1R and reduction of TAMsTGCTApprovalTargeting monocyte/macrophageVimseltinibCSF1RInhibition of the CSF1/CSF1R and reduction of TAMsTGCTApprovalTargeting monocyte/macrophageEganelisib/IPI-549PI3KγPI3Kγ inhibition to reprogram immunosuppressive myeloid-cell and macrophage phenotypesMalignancyPhase Ⅱ (NCT03795610, NCT03980041)ME/CFS myalgic encephalomyelitis/chronic fatigue syndrome, SLE systemic lupus erythematosus, RA rheumatoid arthritis, HS hidradenitis suppurativa, AD atopic dermatitis, ALS amyotrophic lateral sclerosis, CAPS cryopyrin-associated periodic syndromes, CD Crohn’s disease, UC ulcerative colitis, AS ankylosing spondylitis, JIA juvenile idiopathic arthritis, GCA giant cell arteritis, CRS cytokine release syndrome, NMOSD neuromyelitis optica spectrum disorder, CGD chronic granulomatous disease, PNH paroxysmal nocturnal hemoglobinuria, aHUS atypical hemolytic uremic syndrome, gMG generalized myasthenia gravis Summary of therapeutic strategies targeting innate immunity ME/CFS myalgic encephalomyelitis/chronic fatigue syndrome, SLE systemic lupus erythematosus, RA rheumatoid arthritis, HS hidradenitis suppurativa, AD atopic dermatitis, ALS amyotrophic lateral sclerosis, CAPS cryopyrin-associated periodic syndromes, CD Crohn’s disease, UC ulcerative colitis, AS ankylosing spondylitis, JIA juvenile idiopathic arthritis, GCA giant cell arteritis, CRS cytokine release syndrome, NMOSD neuromyelitis optica spectrum disorder, CGD chronic granulomatous disease, PNH paroxysmal nocturnal hemoglobinuria, aHUS atypical hemolytic uremic syndrome, gMG generalized myasthenia gravis PRR-targeting therapeutics As central regulators of innate immunity, PRRs have become important drug targets. This section describes agonists and inhibitors directed at the TLR-IRAK4 pathway, the RLR and cGAS-STING pathway and the NLR inflammasome pathway, highlighting their relevance across multiple diseases. TLR-targeting molecules Pharmacological modulation of TLR signaling has emerged as a promising therapeutic avenue, with strategies spanning receptor agonists, receptor antagonists, and inhibitors of downstream adaptor proteins. These agents exploit the central role of TLRs in pathogen recognition and inflammatory signaling, aiming either to enhance protective immunity or to attenuate pathogenic hyperactivation. TLR agonists TLR agonists mimic microbial nucleic acids or lipoproteins to activate specific TLR subtypes, thereby inducing type I IFNs and proinflammatory cytokines that reinforce antiviral and antitumor immunity. TLR3 agonists such as Rintatolimod and Poly-ICLC are synthetic dsRNAs that act through TRIF to stimulate IRF3/7-driven IFN responses and have been explored in myalgic encephalomyelitis/chronic fatigue syndrome and as vaccine adjuvants or immunotherapies.417 Clinical studies have demonstrated favorable immunogenicity profiles but variable clinical efficacy. In contrast, TLR7 and/or TLR8 agonists such as imiquimod, resiquimod, and vesatolimod promote antiviral and antitumor immunity through induction of type I IFNs and dendritic cell activation. Imiquimod is already approved for actinic keratosis, superficial basal cell carcinoma, and cutaneous warts, whereas vesatolimod has entered phase Ⅱ clinical testing for chronic hepatitis B. Resiquimod has advanced into phase I studies for melanoma.418 TLR antagonists Conversely, TLR antagonists suppress aberrant nucleic acid sensing and downstream IFN production, aiming to mitigate autoimmune and autoinflammatory pathology. Hydroxychloroquine alkalinizes endosomes to disrupt nucleic acid-TLR7/9 interactions, broadly reducing pDC-derived IFN-α.419 Clinically, HCQ remains a mainstay in SLE management, further underscoring the druggability of endosomal TLRs.420 Afimetoran and Enpatoran are selective oral inhibitors of TLR7/8 that are currently in phase Ⅱ trials for SLE, with preliminary data showing a reduction in type I IFN signatures and clinical benefit.421,422 Finally, targeting proximal signaling adaptors such as MyD88 and IRAK4 provides a strategy to dampen convergent inflammatory cascades triggered by multiple TLRs. IRAK4 inhibitors such as PF-06650833 and PROTAC degraders such as KT-474 disrupt MyD88-IRAK4 signaling, suppressing proinflammatory cytokine release.423,424 These compounds have shown potential in rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis in early-phase clinical trials. Collectively, TLR-based therapeutics illustrate the duality of PRR modulation: agonists to harness innate antiviral and adjuvant effects and antagonists to dampen aberrant nucleic acid sensing in autoimmunity. cGAS-STING pathway-targeting molecules Therapeutic targeting of cytosolic nucleic acid sensors, particularly the cGAS-STING pathway, has rapidly advanced as a frontier in innate immunity-based drug discovery. These pathways function as intracellular sentinels for viral and tumor-derived nucleic acids, activating MAVS- and STING-dependent cascades that culminate in TBK1-IRF3-driven type I IFN and inflammatory gene expression. Pharmacological modulation of these axes has demonstrated transformative potential in antiviral therapy, oncology, and autoinflammatory disorders. STING agonists are among the most actively pursued candidates in cancer immunotherapy. Cyclic dinucleotide analogs such as ADU-S100 directly engage STING to induce IFN signaling and promote antitumor immunity, but early intratumoral trials revealed limited systemic efficacy.425 Limited efficacy in trials prompted efforts to optimize delivery platforms and combination regimens with checkpoint inhibitors, chemotherapy, and radiotherapy.426 Macrocycle-bridged STING agonists, such as E7766, and nonnucleotide STING activators, such as SNX281, are in development to overcome pharmacokinetic barriers and broaden clinical applicability.427,428 Conversely, STING antagonists and cGAS inhibitors are gaining traction for IFN-driven autoinflammatory diseases. By suppressing aberrant IFN production, inhibitors such as IMSB301 and VENT-03 hold promise for precision immunotherapy of interferonopathies.428 Overall, RLR and cGAS-STING drugs highlight the therapeutic versatility of innate nucleic acid sensors: agonists amplify antitumor and antiviral immunity, while antagonists mitigate pathogenic IFN signaling. NLR and inflammasome-targeting molecules The NLR family and inflammasomes represent another major class of innate immune sensors being pursued pharmacologically. Inflammasomes, typically nucleated by NLRP3, activate caspase-1 to drive the maturation of IL-1β and IL-18 and induce gasdermin-mediated pyroptosis. Aberrant inflammasome activation contributes to diverse diseases, from CAPS to gout, atherosclerosis, and neurodegeneration. NLRP3 inhibitors are at the forefront of this field. Colchicine represents one of the earliest agents capable of indirectly inhibiting NLRP3 inflammasome activation, conferring anti-inflammatory effects across a spectrum of disorders, including gout, recurrent pericarditis, and FMF. Colchicine exerts its pharmacological activity by binding to tubulin and preventing microtubule polymerization, which secondarily disrupts NLRP3 inflammasome assembly and reduces downstream secretion of IL-1β and IL-18.429 Building upon this indirect paradigm, a new generation of selective and direct small-molecule NLRP3 inhibitors has since been developed, several of which have advanced into early-phase clinical trials targeting autoinflammatory and cardiovascular diseases. Dapansutrile is an oral, selective small-molecule NLRP3 inflammasome inhibitor that prevents NLRP3 assembly/activation and downstream IL-1β maturation, thereby attenuating inflammation in NLRP3-driven conditions and advancing through phase II clinical trials.430 NT-0796 is a next-generation NLRP3 inhibitor that demonstrates central nervous system penetrance and robust pharmacological activity in preclinical models.431 ZYIL1 is an orally available, selective NLRP3 inhibitor that disrupts ASC oligomerization and inflammasome assembly, thereby suppressing NLRP3-driven inflammatory cascades.432 It is currently being evaluated in clinical trials for amyotrophic lateral sclerosis and CAPS. In addition to direct inhibition of NLRP3, therapeutic targeting of its downstream cytokines has yielded clinically validated strategies, which will be discussed in the following sections. Together, inflammasome-targeting drugs exemplify precision immunology: inhibition dampens pathogenic inflammation while preserving host defense. With approved cytokine-targeting agents and a growing clinical pipeline of NLRP3 inhibitors, this field is rapidly translating from experimental biology to clinical medicine. Cytokine-targeting molecules Targeting cytokines has therefore emerged as a transformative therapeutic strategy. Three principal modalities have been developed: (1) monoclonal antibodies that directly neutralize cytokines, (2) soluble cytokine receptors or receptor-Fc fusion proteins that function as decoys to sequester cytokines, and (3) monoclonal antibodies directed against cytokine receptors, preventing downstream signaling. These approaches have provided the foundation for approved biologics and continue to shape the landscape of immunotherapy. Among these, agents directed against TNF-α, the IL-1 family, the IL-6 signaling pathway, and the IFN axis represent the most extensively studied and clinically impactful categories. TNF-α inhibitors TNF-α is a prototypical proinflammatory cytokine, and blockade of TNF-α revolutionized the treatment of chronic inflammatory diseases. TNF-α-binding antibodies include infliximab, which is a chimeric mouse-human IgG1 monoclonal antibody, and adalimumab, which is a fully human IgG1 monoclonal antibody. They have been approved for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriasis.433 Distinct from direct binding, etanercept is a fusion protein comprising the extracellular domain of human TNF receptor 2 linked to the Fc fragment of IgG1.434 This soluble receptor acts as a decoy to sequester TNF-α and TNF-β, thereby preventing receptor activation. Its approved indications include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. IL-1 inhibitors IL-1 is a central mediator of autoinflammatory syndromes. Three therapeutic strategies exemplify the different modalities of cytokine blockade. Canakinumab is a fully human IgG1 monoclonal antibody that selectively neutralizes IL-1β, thereby suppressing downstream inflammation.435 It has demonstrated efficacy in CAPS, systemic juvenile idiopathic arthritis and adult-onset Still’s disease. For cytokine decoy, rilonacept is a dimeric fusion protein consisting of the extracellular domains of IL-1 receptor and IL-1 receptor accessory protein linked to the Fc region of IgG1.436 Acting as a soluble decoy receptor, it captures both IL-1α and IL-1β. Rilonacept was first approved for CAPS and, more recently, for recurrent pericarditis. In contrast, anakinra is a recombinant human IL-1 receptor antagonist that competitively binds IL-1RI, thereby blocking both IL-1α and IL-1β signaling.437 It is approved for rheumatoid arthritis and CAPS. It also rapidly suppresses synovial inflammation to alleviate pain and swelling in gout, particularly in patients with contraindications to NSAIDs, colchicine, or glucocorticoids, showing comparable efficacy to standard anti-inflammatory regimens.438 By dampening inflammasome-driven cytokine cascades, IL-1 inhibitors restore immune homeostasis, providing therapeutic benefit in both rare genetic syndromes and common chronic inflammatory conditions. IL-6 inhibitors IL-6 is a pleiotropic cytokine implicated in chronic inflammation, angiogenesis, and tissue remodeling. Pathogenic IL-6 signaling occurs via both classical and trans-signaling routes, converging on JAK/STAT3 and NF-κB activation. Blockade of IL-6 or its receptor has become central to the management of autoimmune and hyperinflammatory diseases. Siltuximab is a chimeric monoclonal antibody that binds IL-6, blocking receptor interaction.439 It is the only FDA-approved therapy for multicentric Castleman’s disease. More commonly, IL-6 receptor-targeting antibodies have been developed. Tocilizumab is a humanized IgG1 monoclonal antibody against IL-6Rα that prevents both classical and trans-signaling.440 It is approved for rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome (CRS) following CAR-T therapy. Satralizumab is a humanized monoclonal antibody targeting IL-6Rα with Fc engineering to extend the half-life and is approved for neuromyelitis optica spectrum disorder.441 These therapies not only suppress systemic inflammation but also prevent structural tissue damage, underscoring the clinical breadth of IL-6 targeting strategies. IFN signaling modulators The IFN system is indispensable for antiviral defense and immune surveillance, but also drives autoinflammatory disease when dysregulated. Type I IFNs (IFN-α/β) act via IFNAR1/2 to induce ISGs, while IFN-γ enhances macrophage activation and pathogen clearance through IFNGR signaling. Therapeutic modulation of this axis adopts a dual strategy: exogenous IFN supplementation for immunodeficiency and JAK inhibition for interferonopathies. Recombinant IFN-β (IFN-β1a/1b) remains the standard of care in relapsing-remitting multiple sclerosis, significantly reducing the annual relapse rate and delaying disability progression.442 IFN-γ1b is an essential therapy for primary immunodeficiency disorders such as chronic granulomatous disease, where it enhances phagocyte antimicrobial activity via NADPH oxidase activation and significantly reduces rates of severe infections.443 Conversely, in conditions of IFN hyperactivation, JAK1/2 inhibitors, including baricitinib and ruxolitinib, suppress ISG overexpression and ameliorate disease manifestations. Baricitinib is a selective inhibitor of JAK1 and JAK2, thereby attenuating signaling downstream of multiple cytokine receptors, including IL-6, IFN-γ, and GM-CSF, and is approved for the treatment of rheumatoid arthritis and atopic dermatitis.444 Ruxolitinib is a potent JAK1/2 inhibitor that blocks constitutive JAK-STAT signaling, is particularly relevant to myeloproliferative neoplasms driven by JAK2 V617F and other mutations and is approved for myelofibrosis.445 This bidirectional modulation highlights the complexity of IFN biology, necessitating precision approaches to either enhance protective immunity or mitigate pathological inflammation. Complement-targeting molecules Pharmacological strategies targeting the complement cascade have rapidly expanded over the past two decades, progressing from broad replacement therapies to highly selective pathway inhibitors. Three major categories of therapeutic interventions have been established: (1) inhibitors of the initiation of complement (C1q, C1s, C1-INH), (2) blockade of central complement hubs (C3 and C5), and (3) antagonists of the terminal effector phase (C5a/C5aR, C9/MAC). Together, these modalities constitute the backbone of complement therapeutics, with several agents achieving regulatory approval and others advancing through late-phase clinical development. Initiation of complement Targeting the initiation of complement disrupts the earliest steps of complement activation, thereby preventing immune complex-driven inflammation. Key therapeutic approaches include C1q inhibitors, C1s inhibitors, and C1 esterase inhibitors (C1-INH). ANX005, a C1q inhibitor, is a humanized immunoglobulin G4 recombinant antibody against C1q and blocks complement initiation.446 Clinical trials have shown promising efficacy in autoimmune neurological diseases, with phase III trials completed in Guillain-Barré syndrome.447 Sutimlimab is a humanized monoclonal antibody and provides highly selective blockade of C1s-mediated complement activation while sparing the alternative and lectin pathways.448 Its approval for cold agglutinin disease was supported by the CARDINAL and CADENZA phase III trials, which demonstrated significant clinical benefit by reducing hemolysis and improving hemoglobin levels.449 C1-INH acts as a serine protease inhibitor that regulates complement and contact system activation, preventing excessive bradykinin generation and subsequent angioedema attacks.450 Therapeutic products such as Berinert are approved for treating swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat.451 Blockade of central complement hubs C3 and C5 represent pivotal convergence points for all complement pathways, and their inhibition provides broad suppression of complement effector generation. C3 inhibitors such as pegcetacoplan directly block C3/C3b, preventing opsonization and downstream amplification. Pegcetacoplan has received dual approval for geographic atrophy in age-related macular degeneration and for PNH.452,453 C5 inhibitors remain the most validated class, pioneered by eculizumab, which transformed the management of PNH and aHUS, later extending to generalized myasthenia gravis and neuromyelitis optica spectrum disorder.454–457 Ravulizumab shares the same C5 inhibitory mechanism as eculizumab but incorporates Fc-engineering modifications that extend its half-life, thereby markedly reducing dosing frequency.458 Collectively, C3 and C5 blockade has become the cornerstone of complement therapeutics, validated across hematologic, neurologic, and ophthalmologic indications. Antagonists of the terminal effector phase The terminal effector phase of complement can be selectively modulated by targeting C5 activation, C5a-C5aR1 signaling or MAC formation. C5a receptor antagonists, such as avacopan, inhibit C5a-C5aR1 signaling and thereby suppress neutrophil recruitment and endothelial activation. In the phase III ADVOCATE trial, avacopan achieved remission in ANCA-associated vasculitis while reducing steroid exposure, leading to FDA approval in 2021.459 C5a neutralizing antibodies such as vilobelimab selectively block C5a without impairing MAC formation and received FDA Emergency Use Authorization for critically ill COVID-19 patients, supported by the PANAMO study.460 Collectively, terminal pathway inhibition provides a more selective means of complement modulation, validated clinically for C5a/C5aR blockade. Complement-targeted therapeutics have progressed from concept to clinic, with approved agents now spanning the entire cascade from initiation to terminal effectors. C1-INH and C5 inhibitors represent established standards of care, while C1s and C3 inhibitors have validated the potential of selective upstream blockade. Terminal pathway antagonists provide added precision by attenuating inflammatory or cytolytic effectors while preserving upstream immune functions. Future directions will likely emphasize optimized pharmacokinetics, oral small-molecule modulators, and indication expansion into common disorders such as age-related macular degeneration, systemic autoimmunity, and neurodegeneration. Collectively, complement therapeutics exemplify a rapidly maturing field in immunology, translating mechanistic insights into transformative clinical interventions. Innate immune cell-targeting molecules Innate immune cells, especially neutrophils and monocytes/macrophages, represent fundamental effectors of host defense and immune homeostasis. Their dysregulated activation, however, contributes to the pathogenesis of diverse inflammatory, autoimmune, and neoplastic diseases. Accordingly, therapeutic strategies that modulate innate immune cell activity have gained considerable momentum, leading to the development of small molecules, biologics and cellular therapies. Recent advances illustrate a paradigm shift from nonspecific immunosuppression to precision reprogramming of innate effector circuits, providing new opportunities for clinical intervention. Neutrophil-targeted molecules Neutrophils are the most abundant circulating leukocytes and serve as first responders during infection and tissue injury. However, their persistent activation drives pathology in chronic respiratory disorders, autoimmunity, and cancer. Drug development in this area has focused primarily on CXCR2 inhibitors and modulators of neutrophil elastase. Navarixin, a CXCR2 antagonist, is a potent orally available small-molecule antagonist of the C-X-C chemokine receptors CXCR1 and CXCR2, which inhibits the binding of chemokines such as CXCL1 and CXCL8 to their receptors, thereby impeding neutrophil chemotaxis and alveolar recruitment. Clinical trials have demonstrated their potential in COPD and advanced/metastatic solid tumors.461,462 Moreover, neutrophil elastase inhibitors such as sivelestat suppress protease-mediated alveolar epithelial and endothelial injury, thereby mitigating pulmonary inflammation and vascular leakage. Clinically, sivelestat has been approved in Japan and South Korea for the treatment of acute lung injury and ARDS, where it improves oxygenation and reduces ventilator dependence.463 Monocyte/macrophage-targeted molecules Monocytes and macrophages act as central regulators of innate and adaptive immunity, with functional plasticity that can either promote resolution of inflammation or sustain pathological states. Two major therapeutic strategies have been pursued: targeting CSF1R-driven survival pathways and reprogramming macrophage polarization. Among CSF1R inhibitors, pexidartinib was the first FDA-approved drug for tenosynovial giant cell tumors (TGCTs), blocking aberrant CSF1/CSF1R signaling to reduce tumor-associated macrophages.464 More recently, vimseltinib received FDA approval following the successful phase III MOTION trial, confirming CSF1R inhibition as a validated approach for macrophage-dependent tumors.465 Beyond depletion, reprogramming macrophage polarization has emerged as a pivotal therapeutic strategy for targeting TAMs. PI3Kγ is a class IB lipid kinase predominantly expressed in myeloid cells, where it couples G-protein-coupled receptor signaling to the AKT-mTOR/C/EBPβ axis, driving immunosuppressive transcriptional programs and dampening NF-κB activity, thereby sustaining the suppressive phenotype of TAMs and MDSCs within the TME.466 Selective inhibition of PI3Kγ reprograms TAMs from an immunosuppressive M2-like state toward a proinflammatory M1-like phenotype, restoring CD8+ T-cell-mediated cytotoxicity and producing synergistic antitumor activity when combined with checkpoint blockade.467 The first-in-class oral PI3Kγ inhibitor eganelisib (IPI-549) is currently being investigated in multiple phase II clinical trials in combination with other therapies.468 Collectively, these approaches illustrate how innate immune modulation is transitioning from an experimental concept to clinical reality. As next-generation strategies increasingly combine small molecules, antibodies, and engineered cells, targeting innate immune cells is anticipated to become a cornerstone of immunotherapy for cancer, autoimmunity, and hyperinflammatory syndromes. Conclusion and perspectives The past decades have transformed our view of innate immunity from a crude first line of defense to a sophisticated system that orchestrates tissue homeostasis, pathogen clearance, and disease pathogenesis. In this review, we integrate these functional dimensions through a unified recognition-amplification-effector framework. We begin by delineating the core signaling pathways and their multilayered regulation, proceed to discuss how innate immune programs maintain health or contribute to disease when dysregulated, and conclude with a critical appraisal of therapeutics that harness or restrain these pathways. Interactions between microorganisms and the innate immune system provide a representative framework for understanding the core principles of innate immunity. Innate immunity must interpret a complex microbial environment and distinguish harmful signals from tolerated or protective microbial cues to maintain tissue homeostasis. A hallmark of innate immune recognition is PRR diversity, which reflects both the coexistence of multiple receptor families sensing distinct microbial classes and the ability of individual receptors, such as TLR4, to recognize more than one ligand, including bacterial LPS and selected viral proteins.469 In parallel, microorganisms have evolved diverse immune-evasion strategies, including bacterial peptidoglycan N-deacetylation that reduces NOD-dependent sensing, as well as fungal cell-wall masking or remodeling in Candida albicans and Histoplasma capsulatum that limits PRR ligand exposure.470–472 Following recognition, innate immune responses enter a phase of signal amplification that may either be sustained or actively restrained. Pathogens can promote immune evasion by suppressing autophagy, reactive oxygen species production, and inflammatory cytokine signaling, whereas commensal microorganisms often limit excessive inflammation.473 For example, the intestinal commensal fungus Kazachstania pintolopesii secretes a 12-amino-acid peptide fragment of Ygp1 that suppresses epithelial apoptosis and inflammatory responses in the colon.474 In addition, microbial metabolites contribute to immune regulation. Short-chain fatty acids produced by commensals suppress NLRP3 inflammasome activation, reduce IL-1β production, and alleviate intestinal inflammation while strengthening epithelial barrier function.475 Intriguingly, a recent study has further shown that the commensal bacterium Lactobacillus salivarius HHuMin-U restricts norovirus infection by modulating host TBK1-IRF3 and NF-κB signaling pathways.476 However, under pathological conditions such as sepsis, dysregulated innate immune signaling undergoes multilayered amplification.477 This escalation spans intracellular PRR signaling, extracellular cytokine and chemokine propagation, and reciprocal activation among neutrophils, monocytes, macrophages, platelets, and endothelial cells. Importantly, amplification extends beyond the immune system into coagulation through immunothrombosis, a response that may initially limit microbial spread but, when uncontrolled, promotes microvascular occlusion, DIC, and organ dysfunction.478 The effector phase marks the stage at which immune defenses actively eliminate invading microorganisms, but these responses can simultaneously inflict collateral tissue damage. In sepsis, excessive immune activation manifests as cytokine storms, endothelial injury accompanied by pathological vasodilation, and coagulation abnormalities. Persistent exposure to PAMPs or DAMPs may further sustain inflammatory signaling and drive chronic immune activation. Conversely, excessive immune suppression or immune exhaustion can lead to persistent infection and prolonged disease courses. Therefore, maintaining a balanced immune effector response is critical for effective host defense. Although recognition, amplification, and effector phases are separated here for conceptual clarity, they are in fact dynamically intertwined in vivo, forming a highly coordinated innate immune network that ultimately determines the physiological or pathological outcome of host-microbe interactions. Despite major advances, several limitations continue to constrain the field. First, current classification frameworks still fail to fully resolve the heterogeneity, plasticity, and tissue imprinting of innate immune cells, and many subsets remain incompletely defined. This limitation is particularly evident in circulating versus tissue-resident populations, which may share lineage features yet exhibit distinct developmental trajectories and functions. Second, existing experimental systems still cannot fully capture the complexity of innate immunity in vivo, including its cellular heterogeneity, tissue-specific imprinting, and dynamic state transitions. Third, the role of innate immunity remains incompletely understood in many diseases and pathological conditions. Key unresolved issues are whether its activation is protective or pathogenic and which mechanisms govern the shift from host defense to pathological inflammation. Addressing these questions will require a broader understanding of innate immunity at the system level. While individual receptors and signaling pathways have been extensively characterized, their biological effects are strongly influenced by cellular interactions, tissue context, metabolic status, and microbial exposure. As a result, the same innate immune pathway may exert protective or pathogenic effects under different conditions. Further exploration of these interconnected regulatory networks may help explain many unresolved observations in the field and improve the development of more precise therapeutic strategies. Recent technological advances are also providing powerful tools to dissect innate immunity. Single-cell and spatial transcriptomic technologies refine cell classification and reveal tissue-specific functional states.479 Organoid-based platforms improve the modeling of multicellular immune interactions in more realistic microenvironments.480 At the same time, AI and machine learning enhance data integration, pattern recognition, and therapeutic prediction. These advances are also accelerating clinical translation. Therapeutic strategies targeting innate immunity now extend from small-molecule modulators of PRRs and related inflammatory pathways to trained immunity-based interventions and engineered innate immune cell therapies, including CAR-NK and CAR-macrophage platforms.481,482 These approaches broaden the therapeutic scope of innate immunity from pathway blockade to functional immune redirection. However, ethical scrutiny remains essential. A major concern is whether reprogrammed or engineered innate immune cells maintain long-term safety and functional stability, particularly when durable epigenetic or metabolic rewiring is involved. Overall, the recognition-amplification-effector program provides a concise framework for understanding how innate immunity preserves health yet also drives pathology. Future progress will depend on integrating mechanistic depth, physiologically relevant modeling, and clinically actionable technologies to achieve precise and safe manipulation of innate immunity. Acknowledgements This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project of China (No. 2025ZD0549100), the National Natural Science Foundation of China (No. 82550117, 82502735, 82273320, 82472686, and 82572590), the 1·3·5 project of excellent development of discipline of West China Hospital of Sichuan University (No. ZYYC24002), the Research and Development Program, West China Hospital of Stomatology Sichuan University (No. RD-03-202505), and the Postdoctor Research Fund of West China Hospital, Sichuan University (No. 2025HXBH033). Author contributions C.Z. and T.M. wrote the manuscript and designed the figures. X.Z. and J.L. conceived and revised the manuscript. All authors have read and approved the article. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Chaoyu Zou, Teng Ma. Contributor Information Jing Li, Email: lijing1984@scu.edu.cn. Xikun Zhou, Email: xikunzhou@scu.edu.cn. References